

PERSONAL INFORMATION **Wouter de Herder**WORK EXPERIENCE

- September 1985-December 1987 **Resident in training for Internal Medicine**
Deaconess Hospital Refaja, Dordrecht (Netherlands)
- January 1988-December 1990 **Resident in training for Internal Medicine**
Academic Hospital Rotterdam, Dijkzigt, Rotterdam (Netherlands)
- May 1991-June 2011 **staff member - internist - endocrinologist**
Erasmus MC, Rotterdam (Netherlands)
- June 2011- Present **Professor of Endocrine Oncology**
Erasmus MC, Rotterdam (Netherlands)

EDUCATION AND TRAINING

- September 1978-May 1985 **MD**
Erasmus University, Rotterdam (Netherlands)

ADDITIONAL INFORMATION

- Expertise** Endocrine Oncology
- Pituitary
- Adrenal
- Neuroendocrine Tumors

April 1990 Ph.D. thesis 'Enterohepatic circulation of triiodothyronine'

Ph.D. supervisors: Prof. T.J. Visser and Prof. G. Hennemann, Erasmus University, Rotterdam, the Netherlands.

- Publications** 5-2019
PUBLICATIONS W.W. DE HERDER
1. Otten MH, de Herder WW, Hazenberg MP, van de Boom M, Hennemann G (1983) Iodothyronine sulfatase activity of two anaerobic bacterial strains from rat intestinal microflora. FEMS Microbiol Lett 18: 75-77.
 2. de Herder WW, Hazenberg MP, Otten MH, Pennock-Schroder AM, Visser TJ (1985) Hydrolysis of iodothyronine sulfates by sulfatase activity of anaerobic bacteria from the rat intestinal flora. FEMS Microbiol Lett 27: 79-83.
 3. de Herder WW, Hazenberg MP, Pennock-Schroder AM, Visser TJ (1985) Iodothyronine sulfate-hydrolyzing bacteria isolated from human fecal flora. FEMS Microbiol Lett 30: 347-351.
 4. de Herder WW, Hazenberg MP, Pennock-Schroder AM, Hennemann G, Visser TJ (1986) Rapid and bacteria-dependent in vitro hydrolysis of iodothyronine conjugates by intestinal contents of humans and rats. Med Biol 64: 31-35.
 5. de Herder WW, Hazenberg MP, Pennock-Schroder AM, Hennemann G, Visser TJ (1986) Hydrolysis of iodothyronine glucuronides by obligately anaerobic bacteria isolated from human fecal flora. FEMS Microbiol Lett 35: 249-253.

6. de Herder WW, Schroder P, Purnode A, van Vliet ACM, Stricker BHCh (1987) Pirprofen-associated hepatic injury. *J Hepatol* 4: 127-132.
7. Rutgers M, Bonthuis F, de Herder WW, Visser TJ (1987) Accumulation of plasma triiodothyronine sulfate in rats treated with propylthiouracil. *J Clin Invest* 80: 758-762.
8. Hazenberg MP, de Herder WW, Visser TJ (1987) Hydrolysis of iodothyronine conjugates by obligately anaerobic bacteria and intestinal reabsorption of the native hormone. In: proceedings of the IXth international symposium on gnotobiology. Versailles, France. Edition Fondation Marcel Merieux 17, rue Bourgelat, 69002 Lyon, France: 51-53.
9. de Herder WW, Bonthuis F, Rutgers M, Otten MH, Hazenberg MP, Visser TJ (1988) Effects of inhibition of type I iodothyronine deiodinase and phenol sulfotransferase on the biliary clearance of triiodothyronine in rats. *Endocrinology* 122: 153-157.
10. Hazenberg MP, de Herder WW, Visser TJ (1988) Hydrolysis of iodothyronine conjugates by intestinal bacteria. *FEMS Microbiol Rev* 54: 9-16.
11. Visser TJ, Rutgers M, de Herder WW, Eelkman Rooda SJ, Hazenberg MP (1988) Hepatic metabolism, biliary clearance and enterohepatic circulation of thyroid hormone. *Acta Med Austriaca* 15, suppl 1: 37-39.
12. Rutgers M, Heusdens F, Bonthuis F, de Herder WW, Hazenberg MP, Visser TJ (1989) Enterohepatic circulation of triiodothyronine (T3) in rats. Importance of the microflora for the liberation and reabsorption of T3 from biliary T3 conjugates. *Endocrinology* 125: 2822-2830.
13. de Herder WW, Hazenberg MP, Pennock-Schroder AM, Oosterlaken AC, Rutgers M, Visser TJ (1989) On the enterohepatic circulation of triiodothyronine in rats: importance of the intestinal microflora. *Life Sci* 45: 849-856.
14. Visser TJ, van Buuren JCJ, Rutgers M, Eelkman Rooda SJ, de Herder WW (1989) The role of sulfation in thyroid hormone metabolism. *Trends Endocrinol Metab* 1: 211-218.
15. Lamberts SWJ, de Herder WW, Kwekkeboom DJ, Bruining HA, Krenning EP (1992) Het insulinoom en octreotide. *Ned Tijdschr Geneesk* 136: 907-910.
16. Nobels FRE, Kwekkeboom DJ, de Herder WW, Lamberts SWJ (1992) Klinisch niet-functionerende hypofyseadenomen: diagnostische mogelijkheden en therapeutische opties. *Ned Tijdschr Geneesk* 136: 1148-1152.
17. Visser TJ, Kaptein E, Gijzel A, de Herder WW, Ebner T, Burchell B (1993) Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. *FEBS Lett* 324: 358-360.
18. Nobels FRE, Kwekkeboom DJ, Coopmans W, Hoekstra R, de Herder WW, Bouillon R, Lamberts SWJ (1993) A comparison between the diagnostic value of the measurement of gonadotropins, α -subunit and chromogranin A and their response to TRH in clinically nonfunctioning, α -subunit secreting and gonadotroph pituitary adenomas. *J Clin Endocrinol Metab* 77: 784-789.
19. Lamberts SWJ, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP (1993) Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy. *Frontiers in Neuroendocrinology* 14: 27-55.
20. Lamberts SWJ, de Herder WW, Reubi JC, Kwekkeboom DJ, Krenning EP (1993) Somatostatin-receptor imaging of pituitary tumors and its use in their differential diagnosis. *Progress in Endocrinology; The Proceedings of the Ninth International Congress of Endocrinology, Nice 1992*. Mornex, R., Jaffiol, C., Leclere, J. eds., The Parthenon Publishing Group, Carnforth, U.K. p 205-208.
21. Lamberts SWJ, de Herder WW, Kwekkeboom DJ, van der Lely AJ, Nobels FRE, Krenning EP (1993) Current tools in the diagnosis of pituitary tumours. *Acta Endocrinol (Copenh)* 129, Suppl 1: 6-12.
22. Lamberts SWJ, de Herder WW, Reubi J-C, Krenning EPK (1994) A Role of (Labeled) Somatostatin Analogs in the Differential Diagnosis and Treatment of Cushing's Syndrome. *J Clin Endocrinol Metab* 78: 17-19.
23. de Herder WW, Krenning EP, Malchoff CD, Hofland LJ, Reubi J-C, Kwekkeboom DJ, Oei HY, Pols HAP, Bruining HA, Nobels FRE, Lamberts SWJ (1994) Somatostatin receptor scintigraphy: Its value in tumor localization in patients with the Cushing syndrome caused by ectopic corticotropin and/or CRH production. *Am J Med* 96: 305-312.
24. de Herder WW, Uitterlinden P, Pieterman H, Tanghe HLJ, Kwekkeboom DJ, Pols HAP, Singh R, van de Berge JH, Lamberts SWJ (1994) Pituitary tumour localisation in patients with Cushing's disease with magnetic resonance imaging. Is there place for petrosal sinus sampling? *Clin Endocrinol* 40: 87-92.

25. Valk NK, van der Lely AJ, de Herder WW, Lamberts SWJ (1994) The Effects of Human Growth Hormone (GH) Administration in GH-Deficient Adults: A 20-Day Metabolic Ward Study. *J Clin Endocrinol Metab* 79: 1070-1076.
26. van der Lely AJ, de Herder WW, Lamberts SWJ (1994) Pituitary adenomas, some diagnostic and therapeutical aspects. *Pharmacy World & Science* 16: 201-207.
27. Nobels FRE, de Herder WW, Kwekkeboom DJ, Coopmans W, Mulder A, Bouillon R, Lamberts SWJ (1994) Serum chromogranin A in the differential diagnosis of Cushing's syndrome. *Eur J Endocrinol* 131: 589-593.
28. Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. *Digestion* 55 Suppl 3: 54-59.
29. de Herder WW (1995) The localization of endocrine tumours using radionuclide scanning and sampling techniques. *Horm Res* 43: 154-157.
30. de Herder WW, Lamberts SWJ (1995) Imaging of pituitary tumours. *Baill Clin Endocrinol Metab* 9: 367-389.
31. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ (1995) Commentary. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. *Clin Endocrinol* 43: 120-122.
32. de Herder WW, Uitterlinden P, van der Lely AJ, Hofland LJ, Lamberts SWJ (1995) Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein levels in acromegaly. *Eur J Endocrinol* 133: 195-199.
33. de Herder WW, van der Lely AJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ (1995) IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. *Clin Endocrinol* 43: 501-507.
34. Lamberts SWJ, van der Lely AJ, de Herder WW (1995) Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. *J Clin Endocrinol Metab* 80: 3111-3113.
35. Lamberts SWJ, de Herder WW, van Koetsveld PM, Koper JW, van der Lely AJ, Visser-Wisselaar HA, Hofland LJ (1995) Somatostatin receptors: clinical implications for endocrinology and oncology. *Ciba Found Symp* 190: 222-236.
36. Lamberts SWJ, van der Lely AJ, de Herder WW (1995) Clinical and medical diagnosis of acromegaly. *Metabolism* 44, suppl 1: 15-17.
37. Lamberts SWJ, de Herder WW, van der Lely AJ, Hofland LJ (1995) Imaging and medical management of clinically nonfunctioning pituitary tumors. *The Endocrinologist* 5: 3-6.
38. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. *N Engl J Med* 334: 246-254.
39. Visser TJ, Kaptein E, Gijzel A, de Herder WW, Cannon ML, Bonthuis F, de Greef WJ (1996) Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of iodothyronines and other substrates in rats. *Endocrine* 4: 79-85.
40. de Herder WW, van der Lely A-J, Lamberts SWJ (1996) Somatostatin analogue treatment of neuroendocrine tumours. *Postgrad Med J* 72: 403-408.
41. Louwerens M, de Herder WW, Postema PTE, Tanghe HLJ, Lamberts SWJ (1996) Pituitary insufficiency and regression of acromegaly caused by pituitary apoplexy following cerebral angiography. *Eur J Endocrinol* 134: 737-740.
42. de Herder WW, van der Lely AJ, Lamberts SWJ (1996) Verworven hypopituitarisme bij volwassenen; diagnostiek en optimalisatie van substitutietherapie. *Ned Tijdschr Geneesk* 140: 1432-1436.
43. van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SWJ (1996) Acromegalie; diagnostiek en behandeling. *Ned Tijdschr Geneesk* 140: 1436-1440.
44. van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SWJ (1996) Prolactinoom; diagnostiek en behandeling. *Ned Tijdschr Geneesk* 140: 1445-1449.
45. de Herder WW, van der Lely AJ, de Jong FH, Lamberts SWJ (1996) Syndroom van Cushing; optimaliseren van de diagnostiek. *Ned Tijdschr Geneesk* 140: 1449-1454.
46. van Aken MO, Singh R, van den Berge JH, Tanghe HLJ, Pieterman H, de Herder WW (1996) Ziekte van Cushing; succesvollere chirurgie door verbeterde preoperatieve tumorlokalisatie. *Ned Tijdschr Geneesk* 140: 1455-1459.

47. Klootwijk W, de Herder WW, Kwekkeboom DJ, Lamberts SWJ, Krenning EP, Visser TJ, de Greef WJ (1996) High serum levels of the thyrotropin-releasing hormone-like peptide pyroglutamyl-glutamyl-prolineamide in patients with carcinoid tumors. *J Clin Endocrinol Metab* 81: 2816-2820.
48. Ponsen HH, de Herder WW, Bonjer HJ, Wauters CCAP, Krenning EP, Lamberts SWJ (1996) An unusual case of multiple endocrine neoplasia type 1 and the role of 111In-pentetreotide scintigraphy. *Neth J Med* 49: 112-115.
49. de Herder WW, Hofland LJ, Usdin TB, de Jong, FH, Uitterlinden P, van Koetsveld P, Mezey E, Bonner TI, Bonjer HJ, Lamberts SWJ (1996) Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. *J Clin Endocrinol Metab* 81: 3168-3172.
50. Postema PTE, de Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, Bonjer J, van Toor H, Hennemann G, Krenning EP (1996) Somatostatin receptor scintigraphy in non-medullary thyroid cancer. *Digestion* 57 (suppl 1): 36-37.
51. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, Postema PTE, de Herder WW, Valkema R, Kwekkeboom DJ (1996) Somatostatin receptor: scintigraphy and radionuclide therapy. *Digestion* 57 (suppl 1): 57-61.
52. de Herder WW, Lamberts SWJ (1996) Is there a role for somatostatin and its analogs in Cushing's syndrome? *Metabolism* 45 (suppl 1): 83-85.
53. de Herder WW, Kwekkeboom DJ, Reijs AEM, Kooy PPM, Hofland LJ, Krenning EP, Lamberts SWJ (1996) Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In von Werder K, Fahlbusch R, Pituitary adenomas. From basic research to diagnosis and therapy. Elsevier Science BV, Excerpta Medica International Congress Series 1126, 93-104.
54. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SWJ (1996) Peptide receptors in gut endocrine tumours. *Bailliere's Clinical Gastroenterology* 10: 571-585.
55. de Herder WW, Reijs AEM, Kwekkeboom DJ, Hofland LJ, Nobels FRE, Oei HY, Krenning EP, Lamberts SWJ (1996) In vivo imaging of pituitary tumours using a radiolabeled dopamine D2 receptor radioligand. *Clin Endocrinol* 45: 755-767.
56. Bonjer HJ, Bruining HA, Valkema R, Lameris JS, de Herder WW, van der Harst E, Pols HAP (1997) Single radionuclide scintigraphy with 99mTechnetium-Sestamibi and ultrasonography in hyperparathyroidism. *Eur J Surg* 163: 27-32.
57. Bonjer HJ, Bruining HA, Kazemier G, Lange JF, Pols HAP, de Herder WW (1997) Endoscopische retroperitoneale adrenalectomie: een chirurgische aanwinst. *Ned Tijdschr Geneesk* 141: 426-429.
58. Bonjer HJ, Bruining HA, de Herder WW, van Eijck CHJ, Breeman WAP, Krenning EP (1997) Intraoperative nuclear guidance in benign hyperparathyroidism and parathyroid cancer. *Eur J Nucl Med* 24: 246-251.
59. Bonjer HJ, Lange JF, Kazemier G, de Herder WW, Steyerberg EW, Bruining HA (1997) Comparison of three techniques for adrenalectomy. *Br J Surg* 84: 679-682.
60. Klootwijk W, de Boer RDH, Sleddens-Linkels E, Cockle SM, de Herder WW, Bauer K, Visser TJ, de Greef WJ (1997) Urinary excretion of the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in rats. *J Endocrinol* 153: 411-421.
61. Nobels FRE, Kwekkeboom DJ, Coopmans W, Schoenmakers CHH, Lindemans J, de Herder WW, Krenning EP, Bouillon R, Lamberts SWJ (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α -subunit of glycoprotein hormones. *J Clin Endocrinol Metab* 82: 2622-2628.
62. van Aken MO, de Herder WW, van der Lely AJ, de Jong FH, Lamberts SWJ (1997) Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. *Clin Endocrinol* 47: 145-149.
63. van Aken MO, de Marie S, van der Lely AJ, Singh R, van den Berge JH, Poublon RM, Fokkens WJ, Lamberts SWJ, de Herder WW (1997) Risk factors for meningitis after transsphenoidal surgery. *Clin Infect Dis* 25: 852-856.
64. van der Lely AJ, de Herder WW, Lamberts SWJ (1997) The role of radiotherapy in acromegaly. *J Clin Endocrinol Metab* 82: 3185-3186.
65. Klootwijk W, Sleddens-Linkels E, de Boer R, Jansen CA, Autar R, de Herder WW, Boeve ER, Visser TJ, de Greef WJ (1997) Renal clearance of the thyrotropin-releasing hormone-like peptide

- pyroglutamyl-glutamyl-prolineamide in humans. *J Clin Endocrinol Metab* 82: 3068-3073.
66. Hofland LJ, de Herder WW, Visser-Wisselaar HA, van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SWJ (1997) Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. *J Clin Endocrinol Metab* 82: 3011-3018.
67. de Greef WJ, de Herder WW, Lambalk CB, Klootwijk W, Sleddens-Linkels E, de Jong FH, Visser TJ (1997) Evidence that the TRH-like peptide pyroglutamyl-glutamyl-prolineamide in human serum may not be secreted by the pituitary gland. *J Endocrinol* 155: 393-399.
68. van der Lely AJ, de Herder WW, Lamberts SWJ (1997) A risk-benefit assessment of octreotide in the treatment of acromegaly. *Drug Saf* 17: 317-324.
69. van der Lely AJ, de Herder WW, Janssen JAMJL, Lamberts SWJ (1997). Acromegaly: the significance of serum total and free IGF-I and IGF-binding protein-3 in diagnosis. *J Endocrinol* 155 Suppl 1: S9-S13.
70. de Herder WW, van der Lely AJ, Lamberts SWJ (1997) Colorectal cancer screening in acromegaly. Still many unresolved questions. *Clin Endocrinol* 47: 644-646.
71. van der Lely AJ, de Herder WW, Lamberts SWJ (1997) Pituitary tumours. In: *Neuro-Oncology, Part II* (ed. C.J. Vecht), pp. 343-364. Elsevier Science B.V., Amsterdam.
72. Bonjer HJ, Bruining HA, Pols HA, de Herder WW, Proye CA, Carnaille BM, Mohammedamin RS, Steyerberg EW, Breeman WA, Krenning EP (1998) 2-Methoxyisobutylisonitrile probe during parathyroid surgery: tool or gadget? *World J Surg* 22: 507-511.
73. Lamberts SW, Hofland LJ, van der Lely AJ, de Herder WW (1998) Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease. *J Intern Med* 243: 569-571.
74. Lamberts SW, de Herder WW, van der Lely AJ (1998) Pituitary insufficiency. *Lancet* 352: 127-34.
75. N'Diaye N, Tremblay J, Hamet P, de Herder WW, Lacroix A (1998) Adrenocortical overexpression of Gastric Inhibitory Polypeptide receptor underlies food-dependent Cushing's syndrome *J Clin Endocrinol Metab* 83: 2781-2785.
76. Richard K, Hume R, Kaptein E, Sanders JP, van Toor H, de Herder WW, den Hollander JC, Krenning EP, Visser TJ (1998) Ontogeny of iodothyronine deiodinases in human liver. *J Clin Endocrinol Metab* 83: 2868-2874.
77. Bonjer HJ, van der Harst E, Steyerberg EW, de Herder WW, Kazemier G, Lange JF, Mohammedamin, RSA, Bruining HA (1998) Retroperitoneal adrenalectomy: open or endoscopic? *World J Surg* 22: 1246-1249.
78. Alings AM, Fliers E, de Herder WW, Hofland LJ, Sluiter HE, Links TP, van der Hoeven JH, Wiersinga WM (1998) A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis. *J Endocrinol Invest* 21: 703-706.
79. de Herder WW, Reijs AEM, de Swart J, Kaandorp Y, Lamberts SWJ, Krenning EP, Kwekkeboom DJ (1999) Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas. *Eur J Nucl Med*. 26: 46-50.
80. de Herder WW, Lamberts SWJ (1999) Octapeptide somatostatin-analogue therapy of Cushing's syndrome. *Postgrad Med J*. 75: 65-66.
81. de Herder WW, Lamberts SWJ (1999) Tumor localization - the ectopic ACTH syndrome. *J Clin Endocrinol Metab*. 1999 84: 1184-1185.
82. Kwekkeboom DJ, de Herder WW, Krenning EP (1999) Receptor imaging in the diagnosis and treatment of pituitary tumors. *J Endocrinol Invest*. 22: 80-88.
83. Krenning EP, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, van Eijck CHJ, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R (1999) Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. *Ann Oncol*. 10 (suppl. 2): S23-S29.
84. Krenning EP, Valkema R, Pauwels S, Breeman WAP, Bakker WH, de Herder WW, Kwekkeboom DJ, de Jong M (1999) Radiolabeled somatostatin analogue(s): peptide receptor scintigraphy and radionuclide therapy. In: *Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors*. Eds. M Mignon, JF Colombel, John Libbey Eurotext, Montrouge, France, p220-228.
85. van der Lely AJ, de Herder WW, Lamberts SWJ (1999) New medical treatment for acromegaly. *Pituitary*. 2: 89-92.

86. Berends FJ, Bruining HA, de Herder WW, Bonjer HJ (1999) Endoscopic retroperitoneal adrenalectomy. *Acta Chir. Austriaca*. 31: 200-202.
87. van den Bogaert DPM, de Herder WW, de Jong FH, Biemond P, van der Lely AJ, Lamberts SWJ (1999) The continuous 7-hour intravenous dexamethasone suppression test in the differential diagnosis of ACTH-dependent Cushing's syndrome. *Clin Endocrinol*. 51: 193-198.
88. Hofland LJ, de Herder WW, Waaijers M, Zijderwijk J, Uitterlinden P, van Koetsveld PM, Lamberts SWJ (1999) Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas *J Clin Endocrinol Metab*. 84: 3336-3343.
89. Krenning EP, Valkema R, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, van Eijck CHJ, Kwekkeboom DJ, de Jong M, Pauwels S (1999) Scintigraphy and radionuclide therapy with [Indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. *Ital J Gastroenterol Hepatol*. 31 (suppl. 2): S19-S23.
90. Krenning EP, Valkema R, de Jong M, Kooij PPM, Breeman WAP, Bakker WH, de Herder WW, van Eijck CHJ, Kwekkeboom DJ, Kvolts LK, Jamar F, Pauwels S (1999) Radiolabeled somatostatin analogue(s): peptide receptor scintigraphy and radionuclide therapy - risks and promises. In: *Octreotide: The Next Decade*. Ed. SWJ Lamberts, BioScientifica Ltd, Bristol, United Kingdom, pp 49-65.
91. Van der Lely AJ, de Herder WW, Lamberts SWJ (1999) A perspective on the treatment of acromegaly. In: *Octreotide: The Next Decade*. Ed. SWJ Lamberts, BioScientifica Ltd, Bristol, United Kingdom, pp 95-115.
92. Petrossians P, de Herder W, Kwekkeboom D, Lamberigts D, Stevenaert A, Beckers A (2000) Malignant Prolactinoma Discovered by D2 Receptor Imaging *J Clin Endocrinol Metab*. 85: 398-401
93. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M, Jamar F, Pauwels S (2000) The role of radioactive somatostatin and its analogues in the control of tumor growth. *Recent Results Cancer Res*. 153: 1-13.
94. Crougths RJ, Zelissen PM, Van Vroonhoven TJ, Hofland LJ, N'Diaye N, Lacroix A, de Herder WW (2000) GIP-dependent adrenal Cushing's syndrome with incomplete suppression of ACTH. *Clin Endocrinol*. 52: 235-240.
95. Froberg AC, de Herder WW, Bonjer HJ, Krenning EP, Oei HY, Kwekkeboom DJ (2000) Tc-99m sestamibi before and during treatment in a patient with sarcoidosis and persistent hyperparathyroidism. *Clin Nucl Med*. 25: 351-353.
96. Huizenga NA, de Herder WW, Koper JW, de Lange P, van der Lely AJ, Brinkmann AO, de Jong FH, Lamberts SW (2000) Decreased ligand affinity rather than glucocorticoid receptor down-regulation in patients with endogenous Cushing's syndrome. *Eur J Endocrinol*. 142: 472-476.
97. Janssen M, Salm EF, Breburda CS, van Woerkens LJ, de Herder WW, van der Zwaan C, Roelandt JR (2000) Carcinoid crisis during transesophageal echocardiography. *Intensive Care Med*. 26: 254.
98. Huizenga NA, de Lange P, Koper JW, de Herder WW, Abs R, Kasteren JH, de Jong FH, Lamberts SW (2000) Five patients with biochemical and/or clinical generalized glucocorticoid resistance without alterations in the glucocorticoid receptor gene. *J Clin Endocrinol Metab*. 85: 2076-2081.
99. van der Harst E, Bruining HA, Bonjer HJ, van der Ham F, Dinjens WN, Lamberts SW, de Herder WW, Koper JW, Stijnen T, Proye C, Lecomte-Houcke M, Bosman FT, de Krijger RR (2000) Proliferative index in pheochromocytomas: does it predict the occurrence of metastases? *J Pathol*. 191: 175-180.
100. van der Wal BCH, de Krijger RR, de Herder WW, Kwekkeboom DJ, van der Ham F, Bonjer HJ, van Eijck CHJ (2000) Adult hyperinsulinemic hypoglycemia not caused by an insulinoma: a report of two cases. *Virchows Arch*. 436: 481-486.
101. Berends FJ, Cuesta MA, Kazemier G, van Eijck CH, de Herder WW, van Muiswinkel JM, Bruining HA, Bonjer HJ (2000) Laparoscopic detection and resection of insulinomas. *Surgery*. 128: 386-391.
102. de Herder WW, Lamberts SWJ, Tanghe HLJ, Pieterman, H (2000) Bilateral Simultaneous Inferior Petrosal Sinus Sampling (BSIPSS) In: de Herder WW (Editor) *Functional and Morphological Imaging of the Endocrine System*. Endocrine Updates Series, S. Melmed Series Editor. Kluwer Academic Publishers Boston, pp 35-45.

103. de Herder WW, Ferone D, Kwekkeboom D, Lamberts SWJ (2000) Scintigraphy of Pituitary Tumors In: de Herder WW (Editor) Functional and Morphological Imaging of the Endocrine System. Endocrine Updates Series, S. Melmed, Series Editor. Kluwer Academic Publishers Boston, pp 47-58.
104. Krenning EP, de Herder WW, Wiersinga WM, Kwekkeboom DJ (2000) Somatostatin Receptor Scintigraphy in Thyroidal Diseases In: de Herder WW (Editor) Functional and Morphological Imaging of the Endocrine System. Endocrine Updates Series, S. Melmed, Series Editor. Kluwer Academic Publishers Boston, pp 125-141
105. Kwekkeboom DJ, de Herder WW, Krenning EP (2000) Scintigraphy of Pancreatic Neuroendocrine Tumors and Carcinoids In: de Herder WW (Editor) Functional and Morphological Imaging of the Endocrine System. Endocrine Updates Series, S. Melmed, Series Editor. Kluwer Academic Publishers Boston, pp 235-249.
106. de Herder WW (Editor) (2000) Functional and Morphological Imaging of the Endocrine System. Endocrine Updates Series, S. Melmed, Series Editor. Kluwer Academic Publishers Boston, pp 235-249.
107. Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, de Jong FH, Lamberts SW (2000) Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol. 143: 615-621.
108. Bonjer HJ, Sorm V, Berends FJ, Kazemier G, Steyerberg EW, de Herder WW, Bruining HA (2000) Endoscopic retroperitoneal adrenalectomy: lessons learned from 111 consecutive cases. Ann Surg. 232: 796-803.
109. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ (2001) [123I]Metaiodobenzylguanidine and [111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas. J Clin Endocrinol Metab. 86: 685-693.
110. Wessels HT, Hofland LJ, van der Wal R, van Gastel L, van Koetsveld PM, de Herder WW, de Jong FH (2001). In vitro secretion of FSH by cultured clinically nonfunctioning and gonadotroph pituitary adenomas is directly correlated with locally produced levels of activin A. Clin Endocrinol. 54: 485-492.
111. de Herder WW, Lamberts SWJ (2001) Overview of Hyper- and Hypocortisolism. In: Margioris A, Chrousos G.P., Adrenal Disorders. Contemporary Endocrinology Series. Humana Press Inc., Totowa, New Jersey, 143-153.
112. Haslinghuis LM, EP Krenning EP, de Herder WW, Reijs AEM, Kwekkeboom DJ (2001) Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest. 24: 415-422.
113. van Grevenstein WM, de Krijger RR, de Herder WW, Tilanus HW, Bonjer HJ (2001) Abdominal wall metastasis after open resection of an adrenocortical carcinoma. Eur J Surg. 167: 871-387.
114. de Herder WW, Lamberts SW (2002) Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr.Opin.Oncol. 14: 53-57.
115. Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, de Jong FH, Christiansen A, Kam BL, de Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience. Semin. Nucl. Med. 32: 110-122.
116. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH, Boomsma F (2002) The value of plasma markers for the clinical behaviour of pheochromocytomas. Eur J Endocrinol 147: 85-94.
117. Berends FJ, van der Harst EV, Giraudo G, Terkivatan T, Kazemier G, Bruining HA, de Herder WW, Bonjer HJ (2002) Safe retroperitoneal endoscopic resection of pheochromocytomas. World J Surg 26: 527-531.
118. van der Toorn FM, Janssen JAMJL, de Herder WW, Broglio F, Ghigo E, van der Lely AJ (2002) Central ghrelin production does not substantially contribute to systemic ghrelin concentrations; a study in two subjects with active acromegaly Eur J Endocrinol 147: 195-199.
119. van Dam PS, van Gils A, Canninga-van Dijk MR, de Koning EJP, Hofland LJ, de Herder WW (2002) Sequential ACTH and catecholamine secretion in a pheochromocytoma. Eur J Endocrinol 147: 201-206.
120. van den Akker ELT, de Krijger RR, de Herder WW, Drop SLS (2002) Congenital hemihypertrophy and pheochromocytoma, not a coincidental combination? Eur J Pediatr 161:

157-160.

121. Lamberts SW, de Herder WW, Hofland LJ (2002) Somatostatin analogs in the diagnosis and treatment of cancer. *Trends Endocrinol Metab* 13: 451-457.

122. Hofland LJ, de Herder WW, Lamberts SWJ (2002) Resistance to Somatostatin Analogue Therapy. In: *Hormone Resistance and Hypersensitivity States*, Ed.: Chrousos GP. Lippincott Williams & Wilkins, 103-117.

123. van Daele PLA, de Herder WW, Huebner A (2002) Van gen naar ziekte; bijnierinsufficiëntie, achalasie en gestoorde traansecretie: de ziekte van Allgrove. *Ned Tijdschr Geneesk* 146: 2295-2297.

124. de Herder WW (2002) An algorithm for the treatment of gastroenteropancreatic (GEP) neuroendocrine tumors: when to treat; how to treat. In: *Advances in Oncology: The Expanding Role of Octreotide I*. Eds: Lamberts SWJ and Dogliotti L. Bioscientifica Ltd., Bristol, U.K. 143-154.

125. Hofland LJ, de Herder WW, Lamberts SWJ (2002) Mechanism of action of somatostatin and interferon in gastroenteropancreatic tumors. In: *Advances in Oncology: The Expanding Role of Octreotide I*. Eds: Lamberts SWJ and Dogliotti L. Bioscientifica Ltd., Bristol, U.K. 89-102.

126. Feelders RA, Lamberts SW, Hofland LJ, van Koetsveld PM, Verhoef-Post M, Themmen AP, de Jong FH, Bonjer HJ, Clark AJ, van der Lely AJ, de Herder WW (2003) Luteinizing Hormone (LH)-Responsive Cushing's Syndrome: The Demonstration of LH Receptor Messenger Ribonucleic Acid in Hyperplastic Adrenal Cells, which Respond to Chorionic Gonadotropin and Serotonin Agonists in Vitro. *J Clin Endocrinol Metab* 88: 230-237.

127. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP (2003) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. *Eur J Nucl Med Mol Imaging* 30: 417-422.

128. de Herder W, Lamberts S (2003). Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. *Endocrine* 20: 285-290.

129. van der Lely A, de Herder W, Krenning E, Kwekkeboom D (2003). Octreoscan radioreceptor imaging. *Endocrine* 20: 307-312.

130. de Herder WW, van der Lely, AJ (2003). Addisonian crisis and relative adrenal failure. *Reviews in Endocrine & Metabolic Disorders* 4: 143-147.

131. Siccama R, Balk AH, de Herder WW, van Domburg R, Vantrimpont P, van Gelder T (2003). Amiodarone therapy before heart transplantation as a predictor of thyroid dysfunction after transplantation. *J Heart Lung Transplant*. 8: 857-861.

132. de Herder WW, Hofland LJ, van der Lely AJ, Lamberts SWJ (2003) Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. *Endocr Relat Cancer* 10: 451-458.

133. de Herder WW, Hofland LJ (2004) Somatostatin receptors in pheochromocytoma. *Front Horm Res* 31: 145-154.

134. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW (2004). A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. *J Clin Endocrinol Metab*. 89: 638-645.

135. de Herder WW, Krenning EP, van Eijck CH, Lamberts SW (2004) Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas. *Endocr Relat Cancer* 11: 19-34.

136. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. *J Clin Endocrinol Metab* 89:1577-1585.

137. Pivonello R, Ferone D, de Herder WW, Kros JM, Del Basso De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. *J Clin Endocrinol Metab* 89: 2452-2462.

138. Oberg K, Kvols L, Caplin M, Delle FG, de Herder W, Rindi G, Ruzsiewicz P, Woltering EA, Wiedenmann B (2004) Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. *Ann Oncol* 15: 966-973.

139. (2004) Biochemical Assessment and Long-Term Monitoring in Patients with Acromegaly: Statement from a Joint Consensus Conference of The Growth Hormone Research Society and The Pituitary Society. *J Clin Endocrinol Metab* 89: 3099-3102

140. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, Del Basso De Caro ML, Lombardi G, Colao A, Lamberts SW, Hofland LJ

- (2004) Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. *J Clin Endocrinol Metab* 89: 4493-4502.
141. de Herder WW (2004) Insulinoma. *Neuroendocrinology* 80 Suppl 1, 20-2.
142. de Herder WW, Lamberts SW (2004) Gut endocrine tumours. *Best Pract Res Clin Endocrinol Metab* 18: 477-495.
143. Ruzniewski P, Ish-Shalom S, Wymenga M, O'toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B (2004) Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide. *Neuroendocrinology* 80: 244-251.
144. de Herder WW (2004) Reuzengroei. Een historische en medische beschouwing. *Ned Tijdsch Geneesk* 148: 2585-2589.
145. van Aken MO, Feelders RA, de Marie S, van de Berge JH, Dallenga AH, Delwel EJ, Poublon RM, Romijn JA, van der Lely AJ, Lamberts SW, de Herder WW (2004) Cerebrospinal fluid leakage during transsphenoidal surgery: postoperative external lumbar drainage reduces the risk for meningitis. *Pituitary*. 7: 89-93.
146. Bonapart IE, van Domburg R, ten Have SMTH, de Herder WW, Erdman RAM, Janssen JAML and van der Lely AJ (2005) The 'bio-assay' Quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. *Eur J Endocrinol* 152 : 217-224.
147. Krenning EP, Valkema R, Kwekkeboom DJ, de Herder WW, van Eijck CH, de Jong M, Pauwels S, Reubi JC (2005) Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. *J Nucl Med* 46(1 Suppl): 76S-82S.
148. de Herder WW, Lamberts SWJ (2005) Somatostatin analogs as radiodiagnostic tools. *Rev Endocr Metab Disord*. 6: 23-27.
149. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. *Eur J Endocrinol*. 152 : 645-654.
150. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Wiedenmann B, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruzniewski P. (2005) Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours. *Neuroendocrinology*. 80: 394-424.
151. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005). Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. *J Clin Oncol*. 23: 2754-2762.
152. Feenstra J, de Herder WW, ten Have SMTH, van den Beld AW, Feelders RA, Janssen JAMJL, van der Lely AJ (2005). Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. *Lancet* 365: 1644-1646.
153. de Herder WW (2005) A postcard of a giant and his physician (collection W.W. de Herder). *J. Endocrinol Invest* 28: 392
154. de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JAMJL, van der Lely AJ (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. *Eur J Endocrinol* 153: 67-71.
155. de Herder WW (2005) A bronze statue of the tallest acromegalic giant. *J. Endocrinol Invest* 28: 671-672.
156. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW (2005) The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. *Clin Endocrinol* 63: 176-184.
157. de Bruijne ELE, Burgmans JPJ, Krestin GP, Pols HAP, van den Meiracker AH, de Herder WW (2005) Het incidentaloorn van de bijnier: een klinisch probleem van beeldvorming. *Ned Tijdsch Geneesk* 149: 1821-1826.
158. de Herder WW (2005) Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). *Best Practice & Research Clinical Gastroenterology* 19: 705-715.
159. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ, van der Lely AJ, and de Herder WW (2005). Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and

Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels. *J Clin Endocrinol Metab* 90: 6480-6489.

160. Zomerhuis MT, Hussain SM, Feelders RA, van der Lely AJ, de Herder WW (2005) Octreotide Exerts Only Acute, but No Sustained, Effects on MRI Enhancement of Liver Metastases in Carcinoid Syndrome. *Neuroendocrinology* 82: 41-48.

161. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ (2006) IFN- Is a Highly Potent Inhibitor of Gastroenteropancreatic Neuroendocrine Tumor Cell Growth In vitro. *Cancer Res* 66: 554-562

162. van der Lely AJ, de Herder WW (2005). Carcinoid syndrome: diagnosis and medical management. *Arq Bras Endocrinol Metabol.* 5: 850-860.

163. Hanssen WE, Kuhry E, Casseres YA, de Herder WW, Steyerberg EW, Bonjer HJ (2006) Safety and efficacy of endoscopic retroperitoneal adrenalectomy. *Br J Surg.* 93: 715-719.

164. Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW (2005) Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. *J Endocrinol Invest.*28: 36-42.

165. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP (2005) Neuroendocrine tumors and somatostatin: imaging techniques. *J Endocrinol Invest.*28: 132-136.

166. Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant. *Eur J Endocrinol.* 154: 805-806.

167. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A. (2006) Clinical Characterization of Familial Isolated Pituitary Adenomas. *J Clin Endocrinol Metab.* 91: 3316-3323.

168. Roodnat JI, van Gurp EA, Mulder PG, van Gelder T, de Rijke YB, de Herder WW, Kal-van Gestel JA, Pols HA, IJzermans JN, Weimar W. (2006) High Pretransplant Parathyroid Hormone Levels Increase the Risk for Graft Failure after Renal Transplantation. *Transplantation.* 82: 362-367.

169. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG, Kwekkeboom DJ (2006). Effects of Therapy with [177Lu-DOTA0, Tyr3]Octreotate in Patients with Paraganglioma, Meningioma, Small Cell Lung Carcinoma, and Melanoma.. *J Nucl Med.* 47: 1599-606.

170. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B; and all other Frascati Consensus Conference participants (2006). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. *Virchows Arch.* 449: 395-401.

171. de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, Tanghe HL, van der Lely AJ, Kwekkeboom DJ (2006). Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging? *Eur J Endocrinol.* 155: 717-723.

172. van Aken MO, Feelders, RA, de Jong F.H, Pereira AM, Lamberts, SWJ, de Herder WW (2006). Syndroom van Cushing. I. Nieuwe ontwikkelingen in de diagnostiek. *Ned Tijdschr Geneesk* 150: 2359-2364.

173. van Aken MO, Feelders, RA van der Lely AJ, Romijn JA, Lamberts SWJ, de Herder, WW (2006) Syndroom van Cushing. II. Nieuwe behandelingen. *Ned Tijdschr Geneesk* 150: 2365-2369.

174. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP (2006). Somatostatin receptor imaging for neuroendocrine tumors. *Pituitary* 9: 243-248

175. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ (2006). Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. *J Clin Endocrinol Metab* 91: 4537-4543.

176. Korpershoek E, van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A, Lenders JW, Verhofstad AA, de Herder WW, de Krijger RR, Dinjens WN (2006). Genetic analyses of apparently sporadic pheochromocytomas: the rotterdam experience. *Ann N Y Acad Sci.* 1073: 138-148.

177. de Krijger RR, van Nederveen FH, Korpershoek E, de Herder WW, de Muinck Keizer-Schrama SM, Dinjens WN (2006). Frequent genetic changes in childhood pheochromocytomas. *Ann N Y*

Acad Sci. 1073: 166-176.

178. Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH (2006). Expression of activin and inhibin subunits, receptors and binding proteins in Human adrenocortical neoplasms. *Clin Endocrinol (Oxf)*. 65: 792-799.

179. Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, de Herder W, Carney JA, Bertherat J, Gregersen PK, Remmers EF, Stratakis CA. (2006). Adrenal Hyperplasia and Adenomas Are Associated with Inhibition of Phosphodiesterase 11A in Carriers of PDE11A Sequence Variants That Are Frequent in the Population. *Cancer Res*. 66:11571-11575.

180. de Herder WW (2006) Symptomatic medical management of neuroendocrine tumours. In: *Handbook of Neuroendocrine Tumours. Their current and future management*. Eds: Caplin M and Kvols L. Bioscientifica Ltd., Bristol, U.K. 121-132.

181. Rindi G, de Herder WW, O'Toole D, Wiedenmann B (2006). Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: Why Such Guidelines and How We Went about Neuroendocrinology. 84: 155-157.

182. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, Kwekkeboom DJ, Oberg K, Eriksson B, Wiedenmann B, Rindi G, O'toole D, Ferone D (2006). Well-differentiated pancreatic tumor/carcinoma: insulinoma. *Neuroendocrinology*. 84: 183-188.

183. O'Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, Hyrdel R, Nikou G, Krenning E, Vullierme MP, Caplin M, Jensen R, Eriksson B (2006). Rare functioning pancreatic endocrine tumors. *Neuroendocrinology*. 84: 189-195.

184. Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, Lombardi G, Colao A, Lamberts SW, Hofland LJ (2007). Dopamine receptor expression and function in corticotroph ectopic tumors. *J Clin Endocrinol Metab*. 92: 65-68.

185. Hofland J, van Nederveen FH, Timmerman MA, Korpershoek E, de Herder WW, Lenders JW, Verhofstad AA, de Krijger RR, de Jong FH (2007). Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry. *Clin Endocrinol (Oxf)*. 66: 335-340.

186. van Essen M, Krenning EP, Bakker WH, de Herder WW, van Aken MO, Kwekkeboom DJ. (2007) Peptide receptor radionuclide therapy with (177)Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. *Eur J Nucl Med Mol Imaging*. 34: 1219-1227.

187. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G, Raverot G, Barlier A, De Herder W, Penfornis A, Ciccarelli E, Estour B, Lecomte P, Gatta B, Chabre O, Sabate MI, Bertagna X, Garcia Basavilbaso N, Stalldecker G, Colao A, Ferolla P, Wemeau JL, Caron P, Sadoul JL, Oneto A, Archambeaud F, Calender A, Sinilnikova O, Montanana CF, Cavagnini F, Hana V, Solano A, Delettières D, Luccio-Camelo DC, Basso A, Rohmer V, Brue T, Bours V, Teh BT, Beckers A (2007). Aryl Hydrocarbon Receptor Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. *J Clin Endocrinol Metab*. 92: 1891-1896.

188. de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, van der Lely AJ, Kwekkeboom DJ (2007). Diagnostic imaging of dopamine receptors in pituitary adenomas. *Eur J Endocrinol. Suppl 1*: S53-6.

189. Kwekkeboom DJ, Teunissen JJ, Kam BL, Valkema R, de Herder WW, Krenning EP (2007). Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. *Hematol Oncol Clin North Am*. 3: 561-73.

190. de Herder WW (2007). Biochemistry of neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab*. 21: 33-41

191. Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M (2007). Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. *Eur J Nucl Med Mol Imaging*. 11: 1854-1860.

192. Van't Sant HP, Bouvy ND, Kazemier G, Bonjer HJ, Hop WC, Feelders RA, de Herder WW, de Krijger RR (2007). The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. *Histopathology* 51: 239-245.

193. Korpershoek E, Petri BJ, van Nederveen FH, Dinjens WN, Verhofstad AA, de Herder WW, Schmid S, Perren A, Komminoth P, de Krijger RR (2007). Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma. *Endocr Relat Cancer*. 14: 453-462.

194. Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, de Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FC, Speel EJ (2007). DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients. *Endocr Relat Cancer*. 14: 769-779.
195. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007). Long-term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. *J Clin Endocrinol Metab* 92: 4598-4601.
196. Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW (2007). Treatment of severe psychosis due to ectopic Cushing's syndrome. *J Endocrinol Invest*. 30: 776-779.
197. de Vos Tot Nederveen Cappel R, Bouvy N, de Herder W, de Rijke Y, van Toor H, Bonjer J (2007). Novel criteria for parathyroid hormone levels in parathyroid hormone-guided parathyroid surgery. *Arch Pathol Lab Med*. 131: 1800-1804.
198. Rindi G, de Herder WW, O'toole D, Wiedenmann B (2008). Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: The Second Event and Some Final Considerations. *Neuroendocrinology*. 87: 5-7.
199. Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder W, Gross D, Knapp W, Knigge UP, Kulke M, Pape UF (2008). Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma. *Neuroendocrinology* 87: 20-30.
200. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruzsniwski P, Sundin A (2008). Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol*. 9: 61-72.
201. Janszen EWM, van Doorn HC, Ewing PC, de Krijger RR, de Wilt JHW, Kam BLR, de Herder WW (2008). Malignant Struma Ovarii: Good Response after Thyroidectomy and 131I Ablation Therapy. *Clinical Medicine Oncology* 2: 147-152.
202. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ (2008). Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 35: 743-748.
203. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ (2008). Correlation of in vitro and in vivo somatotrophic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. *J Clin Endocrinol Metab*. 93:1412-1417.
204. de Keizer B, van Aken MO, Feelders RA, de Herder WW, Kam BL, van Essen M, Krenning EP, Kwekkeboom DJ (2008). Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA (0),Tyr (3)]octreotate. *Eur J Nucl Med Mol Imaging* 35: 749-755.
205. Alwani RA, Neggers SJ, van der Klift M, Baggen MG, van Leenders GJ, van Aken MO, van der Lely AJ, de Herder WW, Feelders RA (2008). Cushing's syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma. *Pituitary* 12: 280-283.
206. Kos-Kudla B, Bolanowski M, Handkiewicz-Junak D et al. Kos-Kudla B, Bolanowski M, Handkiewicz-Junak D, Jarzab B, Krolicki L, Krzakowski M, Kunikowska J, Nasierowska-Guttmejer A, Nowak A, Rydzewska G, Starzynska T, Szawlowski A; oraz Pozostali Uczestnicy Konferencji Okraglego Stolu (2008). [Diagnostic and therapeutic guidelines for gastrointestinal neuroendocrine tumors (recommended by the Polish Network of Neuroendocrine Tumors)]. *Endokrynol Pol* 59: 41-56.
207. Rydzewska G, Cichocki A, Cwikla J, Kos-Kudla B, Krzyzanowska-Swiniarska B, Nasierowska-Guttmejer A, Szawlowski A, Tomaszewska RA; oraz Pozostali Uczestnicy Konferencji Okraglego Stolu (2008). [Endocrine tumors of the stomach and duodenum (including gastrinoma) - management guidelines (recommended by the Polish Network of Neuroendocrine Tumors)]. *Endokrynol Pol* 59: 57-67.
208. Kos-Kudla B, Bolanowski M, Hubalewska-Dydejczyk A, Krzakowski M, Marek B, Nasierowska-Guttmejer A, Lampe P, Sworczak K; oraz Pozostali Uczestnicy Konferencji Okraglego Stolu (2008). [Pancreatic endocrine tumors - management guidelines (recommended by the Polish Network of Neuroendocrine Tumors)]. *Endokrynol Pol* 59: 68-86.
209. Bolanowski M, Jarzab B, Handkiewicz-Junak D, Jeziorski A, Kos-Kudla B, Zajacki W; oraz

- Pozostali Uczestnicy Konferencji Okraglego Stolu (2008). [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. *Endokrynol Pol.* 59: 87-96.
210. Starzynska T, Szawlowski A, Kos-Kudla B, Krolicki L, Kunikowska J, Nasierowska-Guttmejer A, Rudzki S, Zgliczynski W; oraz Pozostali Uczestnicy Konferencji Okraglego Stolu (2008). [Neuroendocrine tumors of the colon - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. *Endokrynol Pol.* 59: 97-104.
211. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol* 26: 2124-2130.
212. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008). Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. *J Clin Endocrinol Metab.* 93: 3853-3859.
213. Heisterkamp J, de Herder WW, van Dijk LC, van Eijck CH, van den Meiracker AH, Kazemier G (2008). Subtotal adrenalectomy. *Br J Surg* 95: 1075-1076.
214. van Hoek M, Hofland LJ, de Rijke YB, van Nederveen FH, de Krijger RR, van Koetsveld PM, Lamberts SW, van der Lely AJ, de Herder WW, Feelders RA (2009). Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. *J Clin Endocrinol Metab.* 94: 428-433.
215. de Herder WW (2008). Insulinoma. In: *Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach* Editors: Jankowski J, Sampliner R, Kerr D and Fong Y. Blackwell Publishing, Oxford, U.K., 579-580.
216. van der Horst-Schrivers AN, van Ieperen E, Wymenga AN, Boezen HM, Weijmar-Schultz WC, Kema IP, Meijer WG, de Herder WW, Willemse PH, Links TP, de Vries EG (2008). Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours. *Neuroendocrinology* 89: 231-236.
217. de Herder WW (2009). Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). *Pituitary.* 12: 236-244.
218. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ (2009). Co-expression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. *J Clin Endocrinol Metab.* 94:1118-1124.
219. Neggers S, de Herder W, Janssen J, Feelders R, Van der Lely A (2009). Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: Long-term safety up to 4.5 years (median 2.2 yrs) of follow-up in 86 patients. *Eur J Endocrinol.* 60: 529-533.
220. Vitale G, M van Koetsveld P, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SW, Hofland LJ (2009). Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. *Am J Physiol Endocrinol Metab.* 296: E559-566.
221. Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, Teunissen JJ, de Jong M, van Lom K, de Herder WW, Kwekkeboom DJ (2009). Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA (0),Tyr (3)]octreotate. *Eur J Nucl Med Mol Imaging.* 36: 1138-1146.
222. Froberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, Verdijseldonck M, de Herder WW, van der Lugt A, Kooij PP, Krenning EP (2009). Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. *Eur J Nucl Med Mol Imaging.* 36: 1265-1272.
223. Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, de Herder WW, Kwekkeboom DJ (2009). Effects of therapy with [(177)Lu-DOTA (0),Tyr (3)]octreotate on endocrine function. *Eur J Nucl Med Mol Imaging.* 36: 1758-1766.
224. van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derckx P, Riviere J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruine AP, Maher ER, Tissier F, Meatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, Francois J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN. (2009). An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. *Lancet Oncol.* 10: 764-771.
225. Messidoro C, Elte JW, Castro Cabezas M, van Agteren M, Lacroix A, de Herder WW (2009).

- Food-dependent Cushing's syndrome. *Neth J Med.* 67: 187-190.
226. Plockinger U, Wiedenmann B, de Herder WW (2009). ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. *Neuroendocrinology.* 90: 159-161.
227. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. *Neuroendocrinology.* 90: 162-166.
228. Sundin A, Vullierme MP, Kaltsas G, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. *Neuroendocrinology.* 90: 167-183.
229. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. *Neuroendocrinology.* 90: 184-189.
230. Plockinger U, Gustafsson B, Ivan D, Szpak W, Davar J, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography. *Neuroendocrinology.* 90: 190-193.
231. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. *Neuroendocrinology.* 90: 194-202.
232. Akerstrom G, Falconi M, Kianmanesh R, Ruzsiewicz P, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. *Neuroendocrinology.* 90: 203-208.
233. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B, Plockinger U, Mallorca Consensus Conference participants (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biotherapy. *Neuroendocrinology.* 90: 209-213.
234. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. *Neuroendocrinology.* 90: 214-219.
235. Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudla B, de Herder WW, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. *Neuroendocrinology.* 90: 220-226.
236. Arnold R, Chen YJ, Costa F, Falconi M, Gross D, Grossman AB, Hyrdel R, Kos-Kudla B, Salazar R, Plockinger U, Mallorca Consensus Conference participants (2009). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. *Neuroendocrinology.* 90: 227-233.
237. Feelders RA, Hofland LJ, van Aken MO, Neggens SJ, Lamberts SW, de Herder WW, van der Lely AJ (2009). Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. *Drugs.* 69: 2207-2226.
238. van der Hoek J, Hoorn EJ, de Jong GM, Janssens EN, de Herder WW (2009). Severe hyponatremia with high urine sodium and osmolality. *Clin Chem.* 55: 1905-1908.
239. Petri BJ, van Eijck CH, de Herder WW, Wagner A, de Krijger RR (2009). Pheochromocytomas and sympathetic paragangliomas. *Br J Surg.* 96: 1381-1392.
240. de Herder WW (2009). Endocrinology and Art. 4 movie actors with acromegaly/gigantism. *J Endocrinol Invest.* 32: 791-792.
241. Alwani RA, de Herder WW, van Aken MO, van den Berge JH, Delwel EJ, Dallenga AH, De Jong FH, Lamberts SW, van der Lely AJ, Feelders RA (2009). Biochemical Predictors of Outcome of Pituitary Surgery for Cushing's Disease. *Neuroendocrinology.* 91:169-178.
242. Bruynzeel H, Feelders RA, Groenland TH, van den Meiracker AH, van Eijck CH, Lange JF, de Herder WW, Kazemier G (2010). Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma. *J Clin Endocrinol Metab.* 95: 678-685.
243. Kwekkeboom D, Kam B, Van Essen M, Teunissen J, Van Eijck C, Valkema R, De Jong M, de Herder W, Krenning E (2009). Somatostatin receptor based imaging and therapy of

- gastroenteropancreatic neuroendocrine tumors. *Endocr Relat Cancer*. 17: R53-73.
244. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP (2010). Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. *Semin Nucl Med*. 40: 78-88.
245. van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ (2010). Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. *J Nucl Med*. 51:383-390.
246. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW (2010). Pituitary tumours: The sst/D(2) receptors as molecular targets. *Mol Cell Endocrinol*. 26: 89-98.
247. Pavel M, Grossman A, Arnold R, Perren A, Kaltsas G, Steinmuller T, de Herder W, Nikou G, Plockinger U, Lopes JM, Sasano H, Buscombe J, Lind P, O'Toole D, Oberg K (2010). ENETS Consensus Guidelines for the Management of Brain, Cardiac and Ovarian Metastases from Neuroendocrine Tumors. *Neuroendocrinology* 91: 326-332.
248. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW (2010). Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. *N Engl J Med*. 362: 1846-1848.
249. Kos-Kudla B, O'Toole D, Falconi M, Gross D, Kloppel G, Sundin A, Ramage J, Oberg K, Wiedenmann B, Komminoth P, Van Cusem E, Mallath M, Papotti M, Caplin M; Palma de Mallorca Consensus Conference Participants (2010). ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. *Neuroendocrinology*. 91: 341-350.
250. Kaltsas G, Androulakis II, de Herder WW, Grossman AB (2010). Paraneoplastic syndromes secondary to neuroendocrine tumours. *Endocr Relat Cancer*. 17: R173-193.
251. Kvolts LK, Brendtro KL; North American Neuroendocrine Tumor Society (NANETS) (2010). The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. *Pancreas*. 39: 705-706.
252. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasiaka JL, Pommier RF, Yao JC, Jensen RT (2010). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas*. 39: 735-752.
253. Daly AF, Tichomirowa MA, Petrossians P, Heliovaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A, Cazabat L, De Menis E, Montanana CF, Raverot G, Weil RJ, Sane T, Maiter D, Neggers S, Yaneva M, Tabarin A, Verrua E, Eloranta E, Murat A, Vierimaa O, Salmela PI, Emy P, Toledo RA, Sabate MI, Villa C, Popelier M, Salvatori R, Jennings J, Ferrandez Longas A, Labarta Aizpun JI, Georgitsi M, Paschke R, Ronchi C, Valimaki M, Saloranta C, De Herder W, Cozzi R, Guitelman M, Magri F, Lagonigro MS, Halaby G, Corman V, Hagelstein MT, Vanbellighen JF, Barra GB, Gimenez-Roqueplo AP, Cameron FJ, Borson-Chazot F, Holdaway I, Toledo SP, Stalla GK, Spada A, Zacharieva S, Bertherat J, Brue T, Bours V, Chanson P, Aaltonen LA, Beckers A (2010). Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study. *J Clin Endocrinol Metab*. 95(11): E373-383.
254. Feelders RA, Hofland LJ, de Herder WW (2010). Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketoconazole. *Neuroendocrinology*. 92 Suppl 1: 111-115.
255. de Herder WW, Mazzaferro V, Tavecchio L, Wiedenmann B (2010). Multidisciplinary approach for the treatment of neuroendocrine tumors. *Tumori*. 96: 833-846.
256. Neggers SJ, de Herder WW, Feelders RA, van der Lely AJ (2011). Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. *Pituitary*. 14(3): 253-258.
257. Kwekkeboom DJ, de Herder WW, Krenning EP (2011). Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. *Endocrinol Metab Clin North Am*. 40: 173-185.
258. Beukhof CM, van Biezen FC, de Herder WW (2011). Slipped capital femoral epiphysis as manifestation of a rare endocrinological disease. *Neth J Med*. 69(2): 84, 94.
259. Lammens CR, Aaronson NK, Hes FJ, Links TP, Zonnenberg BA, Lenders JW, Majoor-Krakauer D, Van Os TA, Gomez-Garcia EB, de Herder W, van der Luyt RB, van den Ouweland AM, Van Hest LP, Verhoef S, Bleiker EM (2011). Compliance with periodic surveillance for Von-Hippel-Lindau disease. *Genet Med*. 13(6): 519-527.

260. Alwani RA, de Herder WW, de Jong FH, Lamberts SW, van der Lely AJ, Feelders RA (2011). Rapid decrease in adrenal responsiveness to ACTH stimulation after successful pituitary surgery in patients with Cushing's disease. *Clin Endocrinol (Oxf)*. 75(5): 602-607.
261. de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA (2011). New therapeutic options for metastatic malignant insulinomas. *Clin Endocrinol (Oxf)*. 75(3): 277-284.
262. Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR (2011). SDHA Immunohistochemistry Detects Germline SDHA Gene Mutations in Apparently Sporadic Paragangliomas and Pheochromocytomas. *J Clin Endocrinol Metab*. 96(9): E1472-1476.
263. van Os E, Schrama M, Kamphuis K, de Herder WW, Damen GM (2012). Abdominal Pain And Liver Lesions In An Adolescent: Zollinger-Ellison Syndrome. *J Pediatr Gastroenterol Nutr*. 54(3): 435-437.
264. Swarts DR, Claessen SM, Jonkers YM, van Suylen RJ, Dingemans AM, de Herder WW, de Krijger RR, Smit EF, Thunnissen FB, Seldenrijk CA, Vink A, Perren A, Ramaekers FC, Speel EJ (2011). Deletions of 11q22.3-q25 Are Associated with Atypical Lung Carcinoids and Poor Clinical Outcome. *Am J Pathol*. 179(3): 1129-1137.
265. van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, Valkema R, van Nederveen FH, Teunissen JJ, Kwekkeboom DJ, de Herder WW (2011). Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy. *J Clin Endocrinol Metab*. 96(11): 3381-3389.
266. Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, van den Berg G, Pereira AM, de Herder WW, Wagenmakers MA, Kerstens MN, Zelissen PM, Fliers E, Schaper N, Drent ML, Dekkers OM, Gerdes VE (2011). Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. *J Clin Endocrinol Metab*. 96(11): 3525-3532.
267. Alberda WJ, van Eijck CH, Feelders RA, Kazemier G, de Herder WW, Burger JW (2012). Endoscopic bilateral adrenalectomy in patients with ectopic Cushing's syndrome. *Surg Endosc*. 26(4): 1140-1145.
268. de Bruin C, Hofland LJ, Nieman LK, van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, van Essen M, Lamberts SW, de Herder WW, Feelders RA (2012). Mifepristone Effects on Tumor Somatostatin Receptor Expression in Two Patients with Cushing's Syndrome due to Ectopic Adrenocorticotropin Secretion. *J Clin Endocrinol Metab*. 97(2): 455-462.
269. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebowitz D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group (2011). Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 378(9808): 2005-2012.
270. Hofland J, Feelders R, van der Wal R, Kerstens MN, Haak HR, de Herder W, de Jong FH (2012). Serum Inhibin Pro-alphaC is a Tumor Marker for Adrenocortical Carcinomas. *Eur J Endocrinol*. 166(2): 281-289.
271. Kamp K, Damhuis RA, Feelders RA, de Herder WW (2012). Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas (GEP-NET) (2012). *Endocr Relat Cancer*. 19(1): 95-99.
272. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, Rindi G, Kos-Kudla B, Knigge U, Sasano H, Tomassetti P, Salazar R, Ruszniewski P; Barcelona Consensus Conference participants (2012). ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. *Neuroendocrinology*. 95(2): 74-87.
273. Caplin M, Sundin A, Nillson O, Baum RP, Klose KJ, Kelestimur F, Plockinger U, Papotti M, Salazar R, Pascher A; Barcelona Consensus Conference participants (2012). ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. *Neuroendocrinology*. 95(2): 88-97.
274. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants (2012). ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. *Neuroendocrinology*. 95(2): 98-119.
275. Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vulliamme MP, O'Toole D; Barcelona Consensus Conference participants (2012). ENETS

- Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. *Neuroendocrinology*. 95(2): 120-134.
276. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plockinger U, Salazar R, Grossman A; Barcelona Consensus Conference participants (2012). ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejunum-ileum and the appendix including goblet cell carcinomas. *Neuroendocrinology*. 95(2): 135-156.
277. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R; Barcelona Consensus Conference participants (2012). ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology*. 95(2): 157-176.
278. Mokhles P, van Herwerden LA, de Jong PL, de Herder WW, Siregar S, Constantinescu AA, van Domburg RT, Roos-Hesselink JW (2012). Carcinoid heart disease: outcomes after surgical valve replacement. *Eur J Cardiothorac Surg*. 41(6): 1278-1283.
279. van der Pas R, de Bruin C, Leebeek FW, de Maat MP, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Lamberts SW, Hofland LJ, Feelders RA (2012). The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy. *J Clin Endocrinol Metab*. 97(4): 1303-1310.
280. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ (2012). Lutetium-labelled peptides for therapy of neuroendocrine tumours. *Eur J Nucl Med Mol Imaging*. 39 Suppl 1: 103-12.
281. van Dijk SC, de Herder WW, Kwekkeboom DJ, Zillikens MC, Feelders RA, van Schaik RH, van Driel M, van Leeuwen JP (2012). 5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. *Bone*. 50(6): 1260-1265.
282. De Martino MC, van Koetsveld PM, Feelders RA, Spruij-Mooij D, Waaijers MM, Lamberts SW, de Herder WW, Colao AA, Pivonello R, Hofland L (2012). The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. *Endocr Relat Cancer* 19(3): 351-364.
283. de Herder WW (2012). Acromegalic gigantism, physicians and body snatching. Past or present? *Pituitary*. 15 (3): 312-318.
284. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C, Delle Fave G, Fischer L, Fusai G, de Herder WW, Jann H, Komminoth P, de Krijger RR, La Rosa S, Luong TV, Pape U, Perren A, Ruzsniowski P, Scarpa A, Schmitt A, Solcia E, Wiedenmann B (2012). TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study. *J Natl Cancer Inst*. 104(10): 764-777.
285. Granberg D, de Herder W, O'Toole D, Kvols L (2012). Treatment of liver metastases in patients with neuroendocrine tumors. *Int J Hepatol* 790635.
286. Hofland J, Delhanty PJ, Steenbergen J, Hofland LJ, van Koetsveld PM, van Nederveen FH, de Herder WW, Feelders RA, de Jong FH (2012). Melanocortin 2 Receptor-Associated Protein (MRAP) and MRAP2 in Human Adrenocortical Tissues: Regulation of Expression and Association with ACTH Responsiveness. *J Clin Endocrinol Metab*. 97(5): E747-754.
287. de Herder WW (2012). Familial gigantism. *Clinics (Sao Paulo)*. 67 Suppl 1: 29-32.
288. de Herder WW, Eng C (2012). Obesity, diabetes mellitus, and cancer. *Endocr Relat Cancer*. 19(5): E5-7.
289. Frantzen C, Kruizinga RC, van Asselt SJ, Zonnenberg BA, Lenders JW, de Herder WW, Walenkamp AM, Giles RH, Hes FJ, Sluiter WJ, van Pampus MG, Links TP (2012). Pregnancy-related hemangioblastoma progression and complications in von Hippel-Lindau disease. *Neurology*. 79(8): 793-796.
290. Kvols LK, Oberg KE, O'Doriso TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B (2012). Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. *Endocr Relat Cancer*. 19(5): 657-666.
291. van Ginhoven TM, Geilvoet W, de Herder WW, van Eijck CH (2012). Outpatient surgical treatment of primary hyperparathyroidism. *Ned Tijdschr Geneesk*. 156(23): A4408
292. Hermesen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, Nieveen van Dijkum EJ, Haak

- HR; Dutch Adrenal Network (2012). Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery. *Surgery*. 152(1): 50-56.
293. Taieb D, Timmers HJ, Hindie E, Guillet BA, Neumann HP, Walz MK, Opocher G, de Herder WW, Boedeker CC, de Krijger RR, Chiti A, Al-Nahhas A, Pacak K, Rubello D (2012). EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging*. 39(12): 1977-1995.
294. van der Pas R, de Herder WW, Hofland L, Feelders RA (2012). New developments in medical therapy of Cushing's syndrome. *Endocr Relat Cancer*. 19(6): R205-R223.
295. Kanakis G, Kamp K, Tsiveriotis K, Feelders RA, Zorpala A, de Herder WW, Kaltsas G (2013). The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumors (GEP-NET). *Clin Endocrinol (Oxf)*. 78: 950-956.
296. Pieterman CR, van Hulsteijn LT, den Heijer M, van der Luijt RB, Bonenkamp JJ, Hermus AR, Borel Rinkes IH, Vriens MR, Valk GD; DutchMEN1 Study Group (2012). Primary hyperparathyroidism in MEN1 patients: a cohort study with longterm follow-up on preferred surgical procedure and the relation with genotype. *Ann Surg*. 255(6): 1171-1178.
297. van der Pas R, Hofland L, Hofland J, Taylor A, Arlt W, Steenbergen C, van Koetsveld PM, de Herder WW, de Jong FH, Feelders RA (2012). Fluconazole Inhibits Human Adrenocortical Steroidogenesis In Vitro. *J Endocrinol*. 215(3): 403-412.
298. Hofland J, de Herder W, Derks L, Hofland L, Van Koetsveld PM, de Krijger RR, van Nederveen FH, Horvath A, Stratakis CA, de Jong FH, Feelders RA (2012). Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome. *Eur J Endocrinol*. 168(1): 67-74.
299. Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW, de Herder WW, Ferone D, Hofland LJ (2012). Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. *J Clin Endocrinol Metab*. 98(1): E66-71.
300. van der Pas R, Leebeek FW, Hofland LJ, de Herder WW, Feelders RA (2012). Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. *Clin Endocrinol (Oxf)*. 78(4): 481-488.
301. van der Pas R, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Webb SM, Lamberts SW, Hofland LJ, Feelders RA (2013). Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease. *Pituitary*. 16(4): 536-544.
302. Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LJ (2013). Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. *Drugs Today (Barc)*. 49(2): 89-103.
303. Meijer JA, Bakker LE, Valk GD, de Herder WW, de Wilt JH, Netea-Maier RT, Schaper N, Fliers E, Lips P, Plukker JT, Links TP, Smit JA (2013). Radioactive iodine in the treatment of medullary thyroid carcinoma: a controlled multicenter study. *Eur J Endocrinol*. 168(5): 779-86.
304. van Koetsveld PM, Vitale G, Feelders RA, Waaijers M, Sprij-Mooij DM, de Krijger RR, Speel EJ, Hofland J, Lamberts SW, de Herder WW, Hofland LJ (2013). Interferon- is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. *Endocr Relat Cancer*. 20(3): 443-454.
305. de Herder WW (2012). Gastroenteropancreatic neuroendocrine tumors (GEP-NETs). *Best Pract Res Clin Gastroenterol*. 26(6): 689-690.
306. Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, Krenning EP, Kwekkeboom DJ (2012). Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. *Best Pract Res Clin Gastroenterol*. 26(6): 867-881.
307. Hermsen I, Haak HR, de Krijger RR, Kerkhofs T, Feelders RA, de Herder W, Wilmsink H, Smit JW, Gelderblom H, Mirande ND, Eijk R, Wezel TV, Morreau H (2013) Mutational Analyses of EGFR and Downstream Pathways in Adrenocortical Carcinoma. *Eur J Endocrinol*. 169(1): 51-58.
308. van der Weerd K, Van Hagen PM, Schrijver B, Kwekkeboom DJ, de Herder WW, Ten Broek MR, Postema PT, van Dongen JJ, Staal FJ, Dik WA (2013). The peripheral blood compartment in patient with Graves' disease: activated T lymphocytes and increased transitional and pre-naive mature B lymphocytes. *Clin Exp Immunol*. 174(2): 256-64.
309. Hofland J, Steenbergen J, Hofland LJ, M van Koetsveld P, Eijken M, van Nederveen FH, Kazemier G, de Herder WW, Feelders R, de Jong FH (2013). Protein kinase C-induced Activin A

- Switches Adrenocortical Steroidogenesis to Aldosterone by Suppressing CYP17A1 expression. *Am J Physiol Endocrinol Metab.* 305(6): E736-44.
310. van Vliet EI, de Herder WW, de Rijke YB, Zillikens MC, Kam BL, Teunissen JJ, Peeters RP, Krenning EP, Kwekkeboom DJ (2013). Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr 3]octreotate. *Eur J Nucl Med Mol Imaging.* 40(12): 1843-1852.
311. van der Pas R, de Herder WW, Hofland LJ, Feelders RA (2013). Recent Developments in Drug Therapy for Cushing's Disease. *Drugs.* 73(9): 907-918.
312. de Laat JM, Pieterman CR, Weijmans M, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2013). Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. *J Clin Endocrinol Metab.* 98(10): 4143-4151.
313. Veenstra MJ, de Herder WW, Feelders RA, Hofland LJ (2013). Targeting the somatostatin receptor in pituitary and neuroendocrine tumors. *Expert Opin Ther Targets.* 17(11): 1329-1343.
314. Hofland J, Hofland LJ, van Koetsveld PM, Steenbergen J, de Herder WW, van Eijck CH, de Krijger RR, van Nederveen FH, van Aken MO, de Groot JW, Links TP, de Jong FH, Feelders RA (2013). ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11-hydroxylase. *Orphanet J Rare Dis.* 8(1): 142.
315. Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW (2013). Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate. *Endocr Relat Cancer.* 20(6): 825-831.
316. van Adrichem RC, Hofland LJ, Feelders RA, De Martino MC, van Koetsveld PM, van Eijck CH, de Krijger RR, Sprij-Mooij DM, Janssen JA, de Herder WW (2013). Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors. *Endocr Connect.* 2(4): 172-177.
317. Gatto F, Feelders R, van der Pas R, Kros JM, Dogan F, van Koetsveld PM, van der Lelij AJ, Neggers SJ, Minuto F, de Herder W, Lamberts SW, Ferone D, Hofland LJ (2013). -Arrestin 1 and 2 and G Protein-Coupled Receptor Kinase 2 Expression in Pituitary Adenomas: Role in the Regulation of Response to Somatostatin Analogue Treatment in Patients With Acromegaly. *Endocrinology.* 154(12): 4715-4725.
318. de Herder W (2013). Reply. *Neuroendocrinology.* 98(2): 170.
319. Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork (2014). Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. *Endocr Relat Cancer.* 21(3): R153-R163.
320. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group on Neuroendocrine Liver Metastases (2014). Recommendations for management of patients with neuroendocrine liver metastases. *Lancet Oncol.* 15(1): e8-21.
321. Alwani RA, Schmit Jongbloed LW, de Jong FH, van der Lely AJ, de Herder WW, Feelders RA (2014). Differentiating between Cushing's disease and pseudo-Cushing's syndrome: comparison of four tests. *Eur J Endocrinol.* 170(4): 477-486.
322. van den Meiracker AH, van den Berg B, de Herder W, Bakker J (2014). Extreme Blood Pressure Oscillations in a Patient With a MEN-2a Syndrome. *J Clin Endocrinol Metab.* 99(3): 701-702.
323. de Herder WW (2014). GEP-NETS update: functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETS). *Eur J Endocrinol.* 170(5): R173-83.
324. Hermans MA, Stelten BM, Haak HR, de Herder WW, Dercksen MW (2014). Two patients with a neuroendocrine tumour of the small intestine and paraneoplastic myasthenia gravis. *Endocrinol Diabetes Metab Case Rep.* 2014: 140013.
325. De Martino MC, Feelders RA, de Herder WW, van Koetsveld PM, Dogan F, Janssen JA, Waaijers M, Pivonello C, Lamberts SW, Colao AA, de Krijger RR, Pivonello R, Hofland L (2014). Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. *Endocr Relat Cancer.* 21(4): 601-613.
326. Kamp K, Feelders RA, van Adrichem RC, de Rijke YB, van Nederveen FH, Kwekkeboom DJ, de Herder WW (2014). Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): Clinical Features, Diagnosis, Management, and Follow-Up. *J Clin Endocrinol Metab.* 99(9): 3060-3069.

327. de Laat JM, Pieterman CR, van den Broek MF, Twisk JW, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2014). Natural course and survival of neuro-endocrine tumors of thymus and lung in MEN1 patients. *J Clin Endocrinol Metab.* 99(9): 3325-3333.
328. Papathomas TG, Oudijk L, Zwarthoff EC, Post E, Duijkers FA, van Noesel MM, Hofland LJ, Pollard PJ, Maher ER, Restuccia DF, Feelders RA, Franssen GJ, Timmers HJ, Sleijfer S, de Herder WW, de Krijger RR, Dinjens WN, Korpershoek E (2014). Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. *Endocr Relat Cancer.* 21(4): 653-661.
329. de Herder WW (2014). Heroes in endocrinology: Nobel prizes. *Endocr Connect.* 3(3): R94-R104.
330. Hofland J, Steenbergen J, Voorsluijs JM, Verbiest MM, de Krijger RR, Hofland LJ, de Herder WW, Uitterlinden AG, Feelders RA, de Jong FH (2014). Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation. *PLoS One.* 9(8): e104944.
331. Dreijerink KM, Goudet P, Burgess JR, Valk GD; International Breast Cancer in MEN1 Study Group (2014). Breast-cancer predisposition in multiple endocrine neoplasia type 1. *N Engl J Med.* 371(6): 583-584.
332. Korpershoek E, Petri BJ, Post E, van Eijck CH, Oldenburg RA, Belt EJ, de Herder WW, de Krijger RR, Dinjens WN (2014). Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. *Neoplasia.* 16(10): 868-973.
333. Dulfer RR, van Ginhoven TM, Geilvoet W, de Herder WW, van Eijck CH (2014). Operative Treatment of Primary Hyperparathyroidism in Daycare Surgery. *Scand J Surg.* 104(3): 196-199.
334. de Vries MA, Alipour A, Klop B, van de Geijn GJ, Janssen HW, Njo TL, van der Meulen N, Rietveld AP, Liem AH, Westerman EM, de Herder WW, Castro Cabezas M (2015). Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. *Metabolism* 64 (2): 213-217.
335. van der Zwan WA, Bodei L, Mueller-Brand J, de Herder W, Kvols L, Kwekkeboom D (2015). GEP-NETS update: Radionuclide therapy in neuroendocrine tumors. *Eur J Endocrinol.* 172(1): R1-R8.
336. van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Kema IP, Koopmans KP, Valk GD, Timmers HJ, de Herder WW, Feelders RA, Fockens P, Sluiter WJ, de Vries EG, Links TP (2015). EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. *Gastrointest Endosc.* 81(1): 159-167.
337. Lodewijk L, Bongers PJ, Kist JW, Conemans EB, de Laat JM, Pieterman CR, van der Horst-Schrivers AN, Jorna C, Hermus AR, Dekkers OM, de Herder WW, Drent ML, Bisschop PH, Havekes B, Rinkes IH, Vriens MR, Valk GD (2015). Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. *Eur J Endocrinol.* 172(4): 337-342.
338. Vandamme T, Peeters M, Dogan F, Pauwels P, Van Assche E, Beyens M, Mortier G, Vandeweyer G, de Herder W, Van Camp G, Hofland LJ, Op de Beeck K (2015). Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1. *J Mol Endocrinol.* 54(2): 137-147.
339. Beckers A, Lodish M, Giampaolo T, Rostomyan L, Lee M, Faucz FR, Yuan B, Choong C, Caberg JH, Verrua E, Naves LA, Cheetham T, Young J, Lysy P, Petrossians P, Cotterill A, Shah N, Metzger D, Castermans E, Ambrosio MR, Villa C, Strebkova N, Mazerkina N, Gaillard S, Barcelos Barra G, Casulari LA, Neggens S, Salvatori R, Jaffrain-Rea ML, Zacharin M, Lecumberri Santamaria B, Zacharieva S, Lim EM, Mantovani G, Zatelli MC, Collins MT, Bonneville JF, Quezado M, Chittiboina P, Oldfield E, Bours V, Liu P, de Herder WW, Pellegata NS, Lupski JR, Daly AF, Stratakis CA (2015). X-linked acrogigantism (X-LAG) syndrome: clinical profile and therapeutic responses. *Endocr Relat Cancer.* 22(3): 353-367.
340. Bevan J, Newell-Price J, Reynolds R, de Herder W, Anawalt B, Ebeling P, Ball S (2015). Clinical Endocrinology Education Project: a tribute to Professor Steve Judd. *Clin Endocrinol (Oxf).* 82(5): 623.
341. Evenepoel L, Van Nederveen FH, Oudijk L, Papathomas TG, Restuccia DF, Belt EJ, Franssen GJ, Feelders RA, Van Eeden S, Timmers H, de Herder WW, Aydin S, Vikkula M, De Krijger RR, Dinjens WN, Persu A, Korpershoek E (2015). 9B.09: Identification of Markers Predictive for Malignant Behavior of Pheochromocytomas and Paragangliomas. *J Hypertens.* 33 Suppl 1: e122.

342. de Laat JM, Dekkers OM, Pieterman CR, Kluijfhout WP, Hermus AR, Pereira AM, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD (2015). Long-term natural course of pituitary tumors in patients with MEN1: results from the Dutch MEN1 study group (DMSG). *J Clin Endocrinol Metab.* 100(9): 3288-3296.
343. Valdes-Socin H, de Herder WW, Beckers A (2015). The acromegalic voice of Tango: Don Edmundo Rivero. *J Endocrinol Invest.* 38(9): 1023-1024.
344. Rostomyan L, Daly AF, Petrossians P, Natchev E, Lila AR, Lecoq AL, Lecumberri Santamaria B, Trivellin G, Salvatori R, Moraitis A, Holdaway I, Kranenburg-Van Klaveren D, Zatelli MC, Palacios N, Nozieres C, Zacharin M, Ebeling TM, Ojaniemi M, Rozhinskaya L, Verrua E, Jaffrain Rea ML, Filipponi S, Guskova D, Pronin V, Bertherat J, Belaya Z, Ilovaiskaya I, Sahnoun Fathallah M, Sievers C, Stalla GK, Castermans E, Caberg JH, Sorkina E, Auriemma R, Mittal S, Kareva M, Lysy P, Emy P, de Menis E, Choong C, Mantovani G, Bours V, de Herder WW, Brue T, Barlier A, Neggers S, Zacharieva S, Chanson P, Shah N, Stratakis CA, Naves LA, Beckers A (2015). Clinical and genetic characterization of pituitary gigantism: an international study in 208 patients. *Endocr Relat Cancer.* 22(5): 745-757.
345. Nell S, van Leeuwen RS, Pieterman CR, de Laat JM, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Borel Rinkes IH, Vriens MR, Valk GD (2015). No Association of Blood Type O with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. *J Clin Endocrinol Metab.* 100(10): 3850-3855.
346. van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, de Herder WW, Feelders RA, Bonsing BA, Brabander T, Krenning EP, Kwekkeboom DJ (2015). Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. *J Nucl Med.* 56(11): 1647-1653.
347. Neumann HP, de Herder W (2015). Energy and metabolic alterations in predisposition to pheochromocytomas and paragangliomas: the so-called Warburg (and more) effect, 15 years on. *Endocr Relat Cancer.* 22(4): E5-7.
348. Neves CP, Massolt ET, Peeters RP, Neggers SJ, de Herder WW (2015). Pituitary hyperplasia: an uncommon presentation of a common disease. *Endocrinol Diabetes Metab Case Rep.* 2015: 150056.
349. Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J (2015). Consensus on biomarkers for neuroendocrine tumour disease. *Lancet Oncol.* 16(9): e435-446.
350. Creemers SG, Hofland LJ, Korpershoek E, Franssen GJ, van Kemenade FJ, de Herder WW, Feelders RA (2015). Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. *Endocr Relat Cancer.* 23(1): R43-69.
351. Heijneman JA, Boere IA, Feelders RA, de Herder WW, Kros JM, Manintveld OC, Verduijn GM (2015). Catecholamine-induced cardiomyopathy in a patient with malignant paraganglioma. *Neth J Med.* 73(10): 483-486.
352. Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants (2015). Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol.* 26(8): 1604-1620.
353. de Herder WW (2016). The History of Acromegaly. *Neuroendocrinology* 103(1): 7-17.
354. Bergsma H, Konijnenberg MW, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Franssen GJ, van Eijck CH, Krenning EP, Kwekkeboom DJ (2016). Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. *Eur J Nucl Med Mol Imaging.* 43(3): 453-463.
355. De Martino MC, van Koetsveld PM, Feelders RA, Lamberts SW, de Herder WW, Colao A, Pivonello R, Hofland LJ (2016). Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. *Endocrine.* 52(3): 664-667.
356. Kamp K, Alwani RA, Korpershoek E, Franssen GJ, de Herder W, Feelders RA (2016). Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. *Eur J Endocrinol.* 174(3): 271-280.
357. Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papatomas TG, van Nederveen FH, Belt EJ, Franssen GJ, Restuccia DF, Krol NM, van der Lijst RB, Feelders RA, Oldenburg RA, van IJcken

- WF, de Klein A, de Herder WW, de Krijger RR, Dinjens WN (2016). Complex MAX rearrangement in a family with malignant pheochromocytoma, renal oncocytoma and erythrocytosis. *J Clin Endocrinol Metab.*101(2): 453-460.
358. van Adrichem RC, Kamp K, Vandamme T, Peeters M, Feelders RA, de Herder WW (2016). Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. *Ann Oncol.*27(4): 746-747.
359. van Leeuwaarde RS, van Nesselrooij BP, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, de Laat JM, Pieterman CR, Valk GD (2016). Impact of delay in diagnosis in outcomes in MEN1: results from the Dutch MEN1 study group. *J Clin Endocrinol Metab.*101(3): 1159-1165.
360. Delle Fave GF, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage J, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruzsniwski P; all other Vienna Consensus Conference participants (2016). ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. *Neuroendocrinology.* 103(2): 119-124.
361. Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, Oberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, O'Toole D, Krenning E, Reed N, Kianmanesh R; all other Vienna Consensus Conference participants (2016). ENETS Consensus Guidelines Update for Neuroendocrine Neoplasm of the Jejunum and Ileum. *Neuroendocrinology.* 103(2): 125-138.
362. Ramage J, De Herder WW, Delle Fave GF, Ferolla P, Ferone D, Ito T, Ruzsniwski P, Sundin A, Weber W, Zheng-Pei Z, Taal B, Pascher A; all other Vienna Consensus Conference participants (2016). Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms (NEN). *Neuroendocrinology.* 103(2): 139-143.
363. Pape UF, Niederle B, Costa F, Gross D, Kelestimur F, Kianmanesh R, Knigge U, Oberg K, Pavel M, Perren A, Toumpanakis C, O'Connor J, Krenning E, Reed N, O'Toole D; all other Vienna Consensus Conference participants. (2016) Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). *Neuroendocrinology.* 103(2): 144-152.
364. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Kloppel G, Reed N, Kianmanesh R, Jensen RT; all other Vienna Consensus Conference participants (2016). Consensus Guidelines Update for the Management of Functional p-NETs (F-p-NETs) and Non-Functional p-NETs (NF-p-NETs). *Neuroendocrinology.* 103(2): 153-171.
365. Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K; all other Vienna Consensus Conference participants (2016). Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. *Neuroendocrinology.* 103(2): 172-185.
366. Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, Sedlackova E, Toumpanakis C, Anlauf M, Cwikla J, Caplin M, O'Toole D, Perren A; all other Vienna Consensus Conference participants (2016). Consensus Guidelines for High Grade Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumours and Neuroendocrine Carcinomas (NEC). *Neuroendocrinology.* 103(2): 186-194
367. van Adrichem RC, Kamp K, van Deurzen CH, Biermann K, Feelders RA, Franssen GJ, Kwekkeboom DJ, Hofland LJ, de Herder WW (2016). Is there an Additional Value of Somatostatin Receptor Subtype 2A Immunohistochemistry over Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? *Neuroendocrinology.* 103(5): 560-566.
368. de Herder WW (2016). Molecular Imaging of Pituitary Pathology. *Front Horm Res.* 45: 133-141.
369. Vandamme T, Beyens M, de Beeck KO, Dogan F, van Koetsveld PM, Pauwels P, Mortier G, Vangestel C, de Herder W, Van Camp G, Peeters M, Hofland LJ (2016). Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. *Br J Cancer.* 114(6): 650-658.
370. Brabander T, Teunissen JJ, Van Eijck CH, Franssen GJ, Feelders RA, de Herder WW, Kwekkeboom DJ (2016). Peptide receptor radionuclide therapy of neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab.* 30(1): 103-114.
371. de Herder WW, Rehfeld JF, Kidd M, Modlin IM (2016). A short history of neuroendocrine tumours and their peptide hormones. *Best Pract Res Clin Endocrinol Metab.* 30(1): 3-17.

372. Fazio N, Buzzoni R, Baudin E, Antonuzzo L, Hubner RA, Lahner H, de Herder WW, Raderer M, Teule A, Capdevila J, Libutti SK, Kulke MH, Shah M, Dey D, Turri S, Aimone P, Massacesi C, Verslype C (2016). A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. *Anticancer Res.* 36(2): 713-719.
373. Daly AF, Yuan B, Fina F, Caberg JH, Trivellin G, Rostomyan L, de Herder WW, Naves LA, Metzger D, Cuny T, Rabl W, Shah N, Jaffrain-Rea ML, Zatelli MC, Faucz FR, Castermans E, Nanni-Metellus I, Lodish M, Muhammad A, Palmeira L, Potorac I, Mantovani G, Neggers S, Klein M, Barlier A, Liu P, Ouafik L, Bours V, Lupski JR, Stratakis CA, Beckers A (2016). Somatic mosaicism underlies X-linked acrogigantism (XLAG) syndrome in sporadic male subjects. *Endocr Relat Cancer.* 23(4): 221-233
374. van Asselt SJ, Brouwers A, van Dullemen HM, van der Jagt EJ, Bongaerts AH, Koopmans KP, Kema I, Zonnenberg BA, Timmers HJ, de Herder W, Sluiter WJ, de Vries EG, Links TP (2016). Potential value of EUS in pancreatic surveillance of VHL patients. *Eur J Endocrinol.* 174(5): 611-620.
375. van Adrichem RC, de Herder WW, Kamp K, Brugts MP, de Krijger RR, Sprij-Mooij DM, Lamberts SW, van Koetsveld PM, Janssen JA, Hofland LJ (2016). Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform-A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells. *Neuroendocrinology* 103(6): 815-825.
376. de Herder WW (2016). Pareidolia in neuroendocrinology: a pituitary macroadenoma resembling "Big Bird". *J Clin Endocrinol Metab.* 101(4): 1348-1349.
377. Beukhof CM, Medici M, van den Beld AW, Hollenbach B, Hoeg A, Visser WE, de Herder WW, Visser TJ, Schomburg L, Peeters RP (2016). Selenium Status Is Positively Associated with Bone Mineral Density in Healthy Aging European Men. *PLoS One.* 11(4): e0152748.
378. van Adrichem RC, van der Lely AJ, Huisman M, Kramer P, Feelders RA, Delhanty PJ, de Herder WW (2016). Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors? *Endocr Connect.* 5(4): 143-151.
379. Veenstra MJ, van Koetsveld PM, Dogan F, Farrell WE, Feelders RA, Lamberts SW, de Herder WW, Vitale G, Hofland LJ (2016). Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. *Oncotarget.* 9(19): 14791-14802
380. de Vries MA, Klop B, van der Meulen N, van de Geijn GM, Prinzen L, van der Zwan E, Birnie E, Cohen Tervaert JW, Liem AH, de Herder WW, Castro Cabezas M (2016). Leukocyte-bound Apolipoprotein B in the Circulation is Inversely Associated with the Presence of Clinical and Subclinical Atherosclerosis. *Eur J Clin Invest.* 46(8): 690-697.
381. de Jong FH, de Herder WW (2016). Saint Wilgefortis: sudden hirsutism to prevent an unwanted marriage. *J Endocrinol Invest.* 39(12): 1475.
382. Zandee WT, Kamp K, van Adrichem RC, Feelders RA, de Herder WW (2016). Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. *Eur J Endocrinol.* 175(5): 361-366.
383. Creemers SG, van Koetsveld PM, van Kemenade FJ, Papatthomas TG, Franssen GJ, Dogan F, Eekhoff EM, van der Valk P, de Herder WW, Janssen JA, Feelders RA, Hofland LJ (2016). Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. *Endocr Relat Cancer.* 23(9): 727-737.
384. Creemers SG, van Koetsveld PM, van den Dungen ES, Korpershoek E, van Kemenade FJ, Franssen GJ, de Herder WW, Feelders RA, Hofland LJ (2016). Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. *J Clin Endocrinol Metab.* 101(12): 4574-4584.
385. de Laat JM, van der Luijt RB, Pieterman CR, Oostveen MP, Hermus AR, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2016). MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients. *BMC Med.* 14(1): 182.
386. de Vries MA, van der Meulen N, van de Geijn GM, Klop B, van der Zwan EM, Prinzen L, Birnie E, Westerman EM, de Herder WW, Castro Cabezas M (2017). Effect of a Single Dose of Vitamin D3 on Postprandial Arterial Stiffness and Inflammation in Vitamin D-Deficient Women. *J Clin Endocrinol Metab.* 102(3): 992-1000.
387. Angelousi A, Kamp K, Kaltsatou M, O'Toole D, Kaltsas G, de Herder W (2017). Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. *Neuroendocrinology* 105: 394-402.

388. de Vries MA, van Santen SS, Klop B, van der Meulen N, van Vliet M, van de Geijn GM, van der Zwan-van Beek EM, Birnie E, Liem AH, de Herder WW, Castro Cabezas M (2017). Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality. *Eur J Clin Invest.* 47(4): 289-296.
389. Conemans EB, Nell S, Pieterman CR, de Herder WW, Dekkers OM, Hermus AR, van der Horst-Schrivers AN, Bisschop PH, Havekes B, Drent ML, Vriens MR, Valk GD (2017). Prognostic Factors for Survival of MEN1 Patients with Duodenopancreatic Tumors Metastatic to the Liver: Results from the DMSG Study Group. *Endocr Pract.* 23(6): 641-648.
390. Pavel M, de Herder WW (2017). ENETS Consensus Guidelines for the Standard of Care in Neuroendocrine Tumors. *Neuroendocrinology.* 105: 193-195.
391. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossman A, Jensen RT, Kulke M, Oberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. *Neuroendocrinology.* 105: 196-200.
392. Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruzsniwski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D, Antibes Consensus Conference participants (2017) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. *Neuroendocrinology.* 105: 201-211.
393. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, Fazio N, Giammarile F, Hicks RJ, Kjaer A, Krenning E, Kwekkeboom D, Lombard-Bohas C, O'Connor JM, O'Toole D, Rockall A, Wiedenmann B, Valle JW, Vullierme MP, Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. *Neuroendocrinology.* 105: 212-244.
394. Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Horsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW, Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. *Neuroendocrinology.* 105: 245-254.
395. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruzsniwski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M, Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. *Neuroendocrinology* 105: 255-265.
396. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, Costa F, Falkerby J, Fazio N, Gorbounova V, de Herder W, Kulke M, Lombard-Bohas C, O'Connor J, Sorbye H, Garcia-Carbonero R; all other Antibes Consensus Conference Participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. *Neuroendocrinology.* 105: 266-280.
397. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, O'Connor J, Eriksson B, Sorbye H, Kulke M, Chen J, Falkerby J, Costa F, de Herder W, Lombard-Bohas C, Pavel M; all other Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. *Neuroendocrinology.* 105: 281-294.
398. Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Horsch D, Tiensuu Janson E, Ramage J, Antibes Consensus Conference participants (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. *Neuroendocrinology.* 105: 295-309.
399. Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP, Antibes Consensus Conference Participants (2017). ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. *Neuroendocrinology.* 2017: 310-319.
400. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, Krenning EP, Kwekkeboom DJ (2017). Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate (2017). *Endocr Relat Cancer.* 24(5): 243-251.

401. van Leeuwen RS, Dreijerink K, Ausems MG, Beijers HJ, Dekkers OM, de Herder WW, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Peeters PH, Pijnappel RM, Vriens MR, Valk GD (2017). MEN1-dependent breast cancer: indication for early screening? Results from the Dutch MEN1 study group. *J Clin Endocrinol Metab* 102(6): 2083-2090.
402. Kulke MH, Ruzsniwski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC (2017). A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. *Ann Oncol.* 28(6): 1309-1315.
403. van der Weerd K, van Noord C, Loeve M, Knapen MF, Visser W, de Herder W, Franssen GJ, van der Marel CD, Feelders RA (2017). ENDOCRINOLOGY IN PREGNANCY: Case series and review of literature: pheochromocytoma in pregnancy. *Eur J Endocrinol.* 177(2): R49-R58.
404. de Herder WW, Krenning EP, Krestin GP (2017). In memoriam: Dirk J Kwekkeboom (1958-2017). *Endocr Relat Cancer.* 24(5): E1-E2.
405. Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ (2017). Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. *Clin Cancer Res.* 23(16): 4617-4624.
406. Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW (2017). Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. *Clin Endocrinol (Oxf).* 87(2): 165-170.
407. Zandee WT, Kamp K, van Adrichem RCS, Feelders RA, de Herder WW (2017). Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. *Endocr Relat Cancer.* 2017 24(7): R261-R274.
408. Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP (2017). Sorafenib-induced changes in thyroid hormone levels in patients treated for hepatocellular carcinoma. *J Clin Endocrinol Metab.* 102(8): 2922-2929.
409. Zandee WT, de Herder WW, Jann H (2017). Incidence and prognosis of carcinoid syndrome: hormones or tumour burden? *Lancet Oncol.* 18(6): e299.
410. Plantinga TS, Arts P, Knarren GH, Mulder AH, Wakelkamp IM, Hermus AR, Joosten LA, Netea MG, Bisschop PH, de Herder WW, Beijers HJ, de Bruin IJ, Gilissen C, Veltman JA, Hoischen A, Smit JW, Netea-Maier RT (2017). Rare NOX3 Variants Confer Susceptibility to Agranulocytosis during Thyrostatic Treatment of Graves' Disease. *Clin Pharmacol Ther.* 102(6): 1017-1024.
411. Hofland J, Koch AD, de Herder WW (2017). Melaena in a patient with a metastasized neuroendocrine tumor. *Gastroenterology.* pii: S0016-5085(17)35875-4.
412. Galassi FM, Henneberg M, de Herder W, Ruhli F, Habicht ME (2017). Oldest case of gigantism? Assessment of the alleged remains of Sa-Nakht, king of ancient Egypt. *Lancet Diabetes Endocrinol.* 5(8): 580-581.
413. Conemans EB, Brosens LAA, Raicu-Ionita GM, Pieterman CRC, de Herder WW, Dekkers OM, Hermus AR, van der Horst-Schrivers AN, Bisschop PH, Havekes B, Drent ML, Timmers HTM, Offerhaus GJ, Valk GD, Vriens MR (2017). Prognostic value of WHO grade in pancreatic neuro-endocrine tumors in Multiple Endocrine Neoplasia type 1: Results from the DutchMEN1 Study Group. *Pancreatology.* 17(5): 766-772
414. Andreescu CE, Alwani RA, Hofland J, Looijenga LHJ, de Herder WW, Hofland LJ, Feelders RA (2017). Adrenal Cushing's syndrome during pregnancy. *Eur J Endocrinol.* 177(5): K13-K20.
415. Lecoq AL, Stratakis CA, Viengchareun S, Chaligne R, Tosca L, Demeocq V, Hage M, Berthon A, Faucz FR, Hanna P, Boyer HG, Servant N, Salenave S, Tachdjian G, Adam C, Benhamo V, Clauser E, Guiochon-Mantel A, Young J, Lombes M, Bourdeau I, Maiter D, Tabarin A, Bertherat J, Lefebvre H, de Herder W, Louiset E, Lacroix A, Chanson P, Bouligand J, Kamenicky P (2017). Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushing's syndrome. *JCI Insight* 2(18) pii: 92184.
416. Pieterman CRC, de Laat JM, Twisk JWR, van Leeuwen RS, de Herder WW, Dreijerink KMA, Hermus ARMM, Dekkers OM, van der Horst-Schrivers ANA, Drent ML, Bisschop PH, Havekes B, Borel Rinkes IHM, Vriens MR, Valk GD (2017). Long-term Natural Course of Small Non-Functional Pancreatic Neuroendocrine Tumors in MEN1 - Results from the DMSG. *J Clin Endocrinol Metab.* 102(10): 3795-3805.
417. de Hosson LD, Veenendaal LMV, Schuller Y, Zandee WT, de Herder WW, Tesselaaar MET,

Klumpen HJ, Walenkamp AME (2017). Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. *Ann Oncol.* 28(12): 3022-3027.

418. Conemans EB, Raicu-Ionita GM, Pieterman CRC, Dreijerink KMA, Dekkers OM, Hermus AR, de Herder WW, Drent ML, van der Horst-Schrivers ANA, Havekes B, Bisschop PH, Offerhaus GJ, Borel Rinkes IHM, Valk GD, Timmers HTM, Vriens MR (2017). Expression of p27Kip1 and p18Ink4c in human multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. *J Endocrinol Invest.* 41(6): 655-661
419. Salih M, van Kinschot CMJ, Peeters RP, de Herder WW, Duschek EJJ, van der Linden J, van Noord C (2017). Thyrotoxic periodic paralysis: an unusual presentation of hyperthyroidism. *Neth J Med.* 75(8): 315-320.
420. Nell S, Verkooijen HM, Pieterman CR, de Herder WW, Hermus AR, Dekkers OM, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Borel Rinkes IH, Vriens MR, Valk GD (2018). Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results from the DutchMEN1 Study Group. *Ann Surg.* 267(6): 1155-1160.
421. Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLR, Teunissen JJM, de Herder WW, Krenning EP, Kwekkeboom DJ (2018). Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. *J Nucl Med.* 59(3): 452-458.
422. Evenepoel L, van Nederveen FH, Oudijk L, Papatthomas TG, Restuccia DF, Belt EJT, de Herder WW, Feelders RA, Franssen GJH, Hamoir M, Maiter D, Perren A, Timmers HJLM, van Eeden S, Vroonen L, Aydin S, Robledo M, Vikkula M, de Krijger RR, Dinjens WNM, Persu A, Korpershoek E (2018). Expression of Contactin 4 is associated with malignant behavior in pheochromocytomas and paragangliomas. *J Clin Endocrinol Metab.* 103(1): 46-55.
423. Blazevic A, Hofland J, Hofland L, Feelders RA, de Herder WW (2018). Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. *Endocr Relat Cancer.* 25(3): 115-R130.
424. Blazevic A, Zandee WT, Franssen GJH, Hofland J, Van Velthuysen MF, Hofland L, Feelders RA, de Herder WW (2018). Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. *Endocr Relat Cancer.* 25(3): 245-254.
425. Beukhof CM, Massolt ET, Visser TJ, Korevaar TIM, Medici M, de Herder WW, Roeters van Lennep JE, Mulder MT, de Rijke YB, Reiners C, Verburg FA, Peeters RP (2018). Effects of Thyrotropin on Peripheral Thyroid Hormone Metabolism and Serum Lipids. *Thyroid.* 28(2): 168-174.
426. Zandee WT, de Herder WW (2018). The Evolution of Neuroendocrine Tumor Treatment reflected by ENETS Guidelines. *Neuroendocrinology.* 106(4): 357-365.
427. Iacovazzo D, Flanagan SE, Walker E, Quezado R, de Sousa Barros FA, Caswell R, Johnson MB, Wakeling M, Brande M, Guo M, Dang MN, Gabrovska P, Niederle B, Christ E, Jenni S, Sipos B, Nieser M, Frilling A, Dhatariya K, Chanson P, de Herder WW, Konukiewicz B, Kloppel G, Stein R, Korbonits M, Ellard S (2018). MAFA missense mutation causes familial insulinomatosis and diabetes mellitus. *Proc Natl Acad Sci U S A.* 115(5): 1027-1032.
428. Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, Neggers SJMM, Sacre N, van der Lely AJ, Bours V, de Herder WW, Beckers A (2018). Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. *Endocr Relat Cancer.* 25(5): L37-L42.
429. van Leeuwen RS, Pieterman CRC, Bleiker EMA, Dekkers OM, van der Horst-Schrivers AN, Hermus AR, de Herder WW, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2018). High fear of disease occurrence is associated with low quality of life in patients with Multiple Endocrine Neoplasia type 1 (MEN1): Results from the Dutch MEN1 Study Group. *J Clin Endocrinol Metab.* 103(6): 2354-2361
430. Hofland J, Feelders RA, Brabander T, Franssen GJH, de Herder WW (2018). Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours. *Neth J Med.* 76(3): 100-108.
431. da Silva TN, van Velthuysen MLF, van Eijck CHJ, Teunissen JJ, Hofland J, de Herder WW (2018). Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour. *Endocrinol Diabetes Metab Case Rep.* pii: 18-0015.
432. Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van

- Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH (2018). Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial). *BMC Gastroenterol.* 18(1): 84.
433. Conemans EB, Lodewijk L, Moelans CM, Offerhaus GJA, Pieterman CRC, Morsink FH, Dekkers OM, de Herder WW, Hermus AR, van der Horst-Schrivers ANA, Drent ML, Bisschop PH, Havekes B, Brosens LAA, Dreijerink KMA, Borel Rinkes IHM, Timmers HTM, Valk GD, Vriens MR (2018). DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment. *Eur J Endocrinol.* 179(3): 153-160.
434. Jimenez-Fonseca P, Krug S, Tamagno G, Fierro Maya F, Monleon Getino A, Rodriguez Casado CI, Costa F, de Herder WW, Jann H (2018). Identifying prognostic factors for well-differentiated metastatic pancreatic neuroendocrine tumours (pNETs): A retrospective international multicenter cohort study. *Neuroendocrinology.* 107(4): 315-323.
435. de Herder WW (2018). When and How to Use Somatostatin Analogues. *Endocrinol Metab Clin North Am.* 47(3): 549-555.
436. Hofland J, Zandee WT, de Herder WW (2018). Role of biomarker tests for diagnosis of neuroendocrine tumours. *Nat Rev Endocrinol.* 14(11): 656-669.
437. Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Buchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen C, Inzani F, Jann H, Komminoth P, Knigge U, Landoni L, La Rosa S, Lawlor R, Luong T, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt AM, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee W, Zerbi A, Falconi M (2018). Competitive Testing the WHO 2010 vs the WHO 2017 Grading of Pancreas Neuroendocrine Neoplasms: Data From a Large International Cohort Study. *Neuroendocrinology* 107(4): 375-386.
438. Cuny T, de Herder W, Barlier A, Hofland LJ (2018). Role of the tumor microenvironment in digestive neuroendocrine tumors. *Endocr Relat Cancer.* 25(11): R519-R544.
439. Vandamme T, Beyens M, Boons G, Schepers A, Kamp K, Biermann K, Pauwels P, de Herder WW, Hofland L, Peeters M, Van Camp G, Op de Beeck K (2019). Hotspot DAXX, PTCH2 and CYFIP2 mutations in pancreatic neuroendocrine neoplasms. *Endocr Relat Cancer.* 26(1): 1-12.
440. van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, Krenning EP, de Herder WW (2019). Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 46(3): 704-717.
441. de Herder WW, Capdevila J; ENETS 2016 Munich Advisory Board Participants (2019). Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group. *Neuroendocrinology.* 108(1): 5-6.
442. Baudin E, Hayes AR, Scoazec JY, Filosso PL, Lim E, Kaltsas G, Frilling A, Chen J, Kos-Kudla B, Gorbunova V, Wiedenmann B, Nieveen van Dijkum E, Cwikla JB, Falkerby J, Valle JW, Kulke MH, Caplin ME; ENETS 2016 Munich Advisory Board Participants (2019). Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. *Neuroendocrinology.* 108(1): 7-17.
443. Capdevila J, Bodei L, Davies P, Gorbunova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants (2019). Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. *Neuroendocrinology.* 108(1): 18-25.
444. Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants (2019). Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. *Neuroendocrinology.* 108(1): 26-36.
445. Toumpanakis C, Fazio N, Tiensuu Janson E, Horsch D, Pascher A, Reed N, O Apos Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape UF, Grozinsky-Glasberg S, Scoazec JY; ENETS 2016 Munich Advisory Board Participants (2019). Unmet Needs in Appendiceal Neuroendocrine Neoplasms. *Neuroendocrinology.* 108(1): 37-44.
446. Ramage JK, Valle JW, Nieveen van Dijkum EJM, Sundin A, Pascher A, Couvelard A, Kloppel G; ENETS 2016 Munich Advisory Board Participants (2019). Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. *Neuroendocrinology.* 108(1): 45-53.
447. Sorbye H, Baudin E, Borbath I, Caplin M, Chen J, Cwikla JB, Frilling A, Grossman A, Kaltsas G, Scarpa A, Welin S, Garcia-Carbonero R; ENETS 2016 Munich Advisory Board Participants

- (2019). Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3). *Neuroendocrinology*. 108(1): 54-62.
448. Herrera-Martinez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Galvez Moreno MA, Luque RM, Castano JP, de Herder WW, Feelders RA (2019). Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. *Drugs*. 79(1): 21-42.
449. Zandee WT, Brabander T, Blazevic A, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, de Herder WW (2019). Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. *J Clin Endocrinol Metab*. 104(4): 1336-1344.
450. Hofland J, Herrera Martinez AD, Zandee WT, de Herder WW (2019). Management of carcinoid syndrome: a systematic review and meta-analysis. *Endocr Relat Cancer*. 26(3): R145-R156.
451. Herrera-Martinez AD, Hofland LJ, Galvez Moreno MA, Castano JP, de Herder WW, Feelders RA (2019). Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. *Endocr Relat Cancer*. 26(3): R157-R179.
452. Creemers SG, van Koetsveld PM, de Herder WW, Dogan F, Franssen GJH, Feelders RA, Hofland L (2019). MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer. *Endocr Relat Cancer*. 26(3): 367-378.
453. De Martino MC, van Koetsveld PM, Feelders RA, de Herder WW, Dogan F, Janssen JAMJL, Hofste Op Bruinink D, Pivonello C, Waaijers AM, Colao A, de Krijger RR, Pivonello R, Hofland LJ (2019). IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. *Endocrine*. 64(3): 673-684.
454. Herrera Martinez AD, van den Dungen R, Dogan F, van Koetsveld PM, Culler M, de Herder WW, Luque RM, Feelders RA, Hofland L (2019). Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. *Endocr Relat Cancer*. 26(6): 585-599.
455. Beukhof CM, Brabander T, van Nederveen FH, van Velthuisen MF, de Rijke YB, Hofland LJ, Franssen GJH, Froberg LAC, Kam BLR, Visser WE, de Herder WW, Peeters RP (2019). Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. *BMC Cancer*. 19(1): 325.
456. Hofland J, Brabander T, de Herder WW (2019). Letter to the editor: The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study. *J Clin Endocrinol Metab*. 104(11):5104-5105.
457. Hofland J, de Herder WW, Kann PH (2019). Turning up the heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms. *J Clin Endocrinol Metab*. 104(11):5053-5055.
458. Zandee WT, Feelders RA, Smit Duijzentkunst D, Hofland J, Metselaar RM, Oldenburg RA, van Linge A, Kam BLR, Teunissen J, Korpershoek E, Hendriks J, Abusaris H, Slagter C, Franssen GJH, Brabander T, de Herder W (2019). Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. *Eur J Endocrinol*. 181(1): 45-53.
459. Herrera-Martinez AD, Feelders RA, de Herder WW, Castano JP, Galvez Moreno MA, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ (2019). Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. *Horm Cancer*. 10(2-3): 107-119.
460. van Beek DJ, Nell S, Pieterman CRC, de Herder WW, van de Ven AC, Dekkers OM, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, Borel Rinkes IHM, Vriens MR, Valk GD (2019). Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG). *J Surg Oncol*. 120(6): 966-975.
461. de Herder WW (2020). Clementine Delait (1865-1934), the most famous bearded lady on the continent in the 20th century. *Gynecol Endocrinol*. 36(3): 213-217.
462. Herrera-Martinez AD, Feelders RA, Van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Castano JP, de Herder W, Hofland LJ (2020). Efficacy of the tryptophan hydroxylase inhibitor telotristat on growth and serotonin secretion in 2D and 3D cultured pancreatic neuroendocrine tumor cells. *Neuroendocrinology*. 110(5): 351-363.
463. Hofland J, Kaltsas G, de Herder WW (2020). Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. *Endocr Rev*. 41(2): 1-33.
464. Boguszewski CL, Boguszewski MCDS, de Herder WW (2020). From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. *Growth Horm IGF Res*. 50: 48-56.
465. van Koetsveld PM, Creemers SG, Dogan F, Franssen GJH, de Herder WW, Feelders RA, Hofland LJ (2020). The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. *J*

466. de Herder WW (2020). Toni Mochty : Bardet Biedl syndrome "avant la lettre". Clin Genet. 97(3): 536-537.
467. Burggraaf B, Pouw N, Fernandez Arroyo S, van Vark-van der Zee Lc LC, van de Geijn GM, Birnie E, Huisbrink J, van der Zwan EM, Mulder MT, Rensen PCN, de Herder WW, Castro Cabezas M (2020). A Placebo-controlled Proof-of-Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin-treated patients with Type 2 Diabetes Mellitus. Diabetes Obes Metab. 22(5): 807-816.
468. Zandee WT, van der Zwan JM, de Herder WW, van Velthuysen MF (2020). Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough. Neuroendocrinology. 110(11-12): 994-1000.
469. Armocida E, Bianucci R, Varotto E, de Herder WW, Galassi FM (2020). Hereditary acromegalic gigantism in the family of Roman Emperor Maximinus Thrax. Med Hypotheses. 136:109525.
470. Braat AJAT, Bruijnen RCG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwen RS, van Treijen MJC, de Herder WW, Hofland J, Tesselaar MET, de Jong HWAM, Lam MGEH (2020). Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 21(4): 561-570.
471. Coopmans EC, Muhammad A, Daly AF, de Herder WW, van Kemenade FJ, Beckers A, de Haan M, van der Lely AJ, Korpershoek E, Neggers SJCM (2020). The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study. Endocrine. 68(3): 640-649.
472. Lourenco DM Jr, de Herder WW. Editorial: Early Genetic and Clinical Diagnosis in MEN1 (2020). Front Endocrinol (Lausanne). 11: 218.
473. van den Broek MFM, van Nesselrooij BPM, Pieterman CRC, Verrijn Stuart AA, van de Ven AC, de Herder WW, Dekkers OM, Drent ML, Havekes B, Kerstens MN, Bisschop PH, Valk GD (2020). Clues For Genetic Anticipation In Multiple Endocrine Neoplasia Type 1. J Clin Endocrinol Metab. 105(7): e2491-e2500.
474. Bodei L, Bergsland EK, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska JA, Pavel M, Reidy-Lagunes DL, Siveke J, Strosberg JR, Dittmer U, Herrmann K (2020). Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns? J Nucl Med. 61(8): 1094-1095.
475. de Mestier L, Couvelard A, Blazevic A, Hentic O, de Herder WW, Rebours V, Paradis V, Ruszniewski P, Hofland LJ, Cros J (2020). Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocr Relat Cancer. 27(10): R391-R405.
476. Refardt J, Zandee WT, Brabander T, Feelders RA, Franssen GJH, Hofland LJ, Christ E, de Herder WW, Hofland J (2020). Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. Endocr Relat Cancer. 27(11): 615-624.
477. Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S (2020). Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer. 144: 200-214.
478. Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasinska-Cwikla A, Zandee W, Laskaratos F, de Mestier L, Lamarca A, Hernando J, Cwikla J, Strosberg J, de Herder W, Caplin M, Cives M, van Leeuwen R. (2021) Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is 10%? The Oncologist. 26: 294-301
479. van den Broek MFM, de Laat JM, van Leeuwen RS, van de Ven AC, de Herder WW, Dekkers OM, Drent ML, Kerstens MN, Bisschop PH, Havekes B, Hackeng WM, Brosens LAA, Vriens MR, Buikhuisen WA, Valk GD (2021). The management of neuroendocrine tumors of the lung in MEN1: results from the Dutch MEN1 Study Group. J Clin Endocrinol Metab. 106(2): e1014-e1027.
480. Merola E, Zandee WT, de Mestier L, Klumpen HJ, Makulik K, Geboes K, van Velthuysen ML, Couvelard A, Cros J, van Eeden S, Hoorens A, Stephenson T, Zajacki W, de Herder WW, Munir A (2021). Histopathological Revision for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms in Expert Centers: Does it Make the Difference? Neuroendocrinology. 111: 170-177.
481. van Leeuwen RS, Pieterman CRC, May AM, Dekkers OM, van der Horst-Schrivers ANA, Hermus AR, de Herder W, Drent ML, Bisschop PH, Havekes B, Vriens MR, Valk GD (2021). Health-related quality of life in patients with Multiple Endocrine Neoplasia type 1. Neuroendocrinology. 111(3): 288-296.

482. Zandee WT, Hofland J, de Herder WW (2021). Should everolimus be stopped after radiological progression in metastatic insulinoma? A "pro" point of view. *Endocrine*. 71(1): 256-257.
483. Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Horsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A; ESMO Guidelines Committee (2021). Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 32(4): 439-451.
484. Blazevic A, Brabander T, Zandee WT, Hofland J, Franssen GJH, van Velthuysen MF, Feelders RA, De Herder WW (2021). Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. *Cancers (Basel)*. 13(3): 443.
485. van Beek DJ, Nell S, Vorselaars WCM, Bonsing BA, van Eijck CHJ, van Goor H, Nieveen van Dijkum EJ, Dejong CHC, Valk GD; DutchMEN Study Group (DMSG), Borel Rinkes IHM, Vriens MR (2021). Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort. *Ann Surg Oncol*.
486. Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Oberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taieb D, Virgolini I, Wild D, Herrmann K, Yao J (2021). Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. *Eur J Cancer*. 146: 56-73.
487. Minczeles NS, Hofland J, de Herder WW, Brabander T (2021). Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. *Curr Oncol Rep*. 23(4): 46.
488. Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru A, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K (2021). High-specific-activity ¹³¹I-MIBG vs ¹⁷⁷Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. *Clin Cancer Res*. 27(11):2989-2995.
489. Zandee WT, Brabander T, Blazevic A, Minczeles NS, Feelders RA, de Herder WW, Hofland J (2021). Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome. *J Clin Endocrinol Metab*.
490. Lima Ferreira J, Marques B, Menke-van der Houven van Oordt CW, de Herder WW, Brabander T, Hofland J (2021). Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. *Endocrinol Diabetes Metab Case Rep*. 20-0172.
491. Blazevic A, Starmans MPA, Brabander T, Dwarkasing RS, van Gils RAH, Hofland J, Franssen GJH, Feelders RA, Niessen WJ, Klein S, de Herder WW (2021). Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics. *Endocr Relat Cancer*. 28(8): 529-539.
492. de Herder WW (2021). Aldo Molinari: the wedding of the giant Almiro Crema in Torino. *J Endocrinol Invest*.
493. Fazio N, Gervaso L, Halfdanarson TR, La Salvia A, Hofland J, Hernando J, Sonbol MB, Garcia-Carbonero R, Capdevila J, de Herder WW, Koumariou A, Kaltsas G, Rossi M, Grozinsky-Glasberg S, Oleinikov K, Boselli S, Tamayo D, Bagnardi V, Laffi A, Rubino M, Spada F (2021). Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. *Eur J Cancer*. 154: 246-252.

Projects RESEARCH PROJECTS

- 2003 Research Grant from ZonMw: "Moleculair-genetische analyse en gen expressie profiling als parameters voor het klinische gedrag van pheochromocytomen". Principal investigator: Dr. R.R. de Krijger, Erasmus MC, Rotterdam, the Netherlands.
- 2004 Research Grant from ZonMw: "Op DNA micro-array gebaseerde gen expressie profiling: een nieuwe diagnostische test voor het bepalen van het klinische gedrag van pheochromocytomen". Principal investigator: Dr. R.R. de Krijger, Erasmus MC, Rotterdam, the Netherlands.
- 2004 Research Grant from Vanderes Foundation: "The role of beta-interferon and interferon receptors in the pathogenesis and therapy of adrenal cancer". Principal investigator: Dr. L.J. Hofland, Erasmus MC, Rotterdam, the Netherlands.
- 2004 Sexual dysfunction in patients with a carcinoid tumour (principal investigator).
- 2005 Research Grant from ZonMw: "Op DNA micro-array gebaseerde gen expressie profiling: een nieuwe diagnostische test voor het bepalen van het klinische gedrag van pheochromocytomen".

Principal investigator: Dr. R.R. de Krijger, Erasmus MC, Rotterdam, the Netherlands.

2006 Research Grant from ZonMw: "Moleculaire mechanismen in het ontstaan van maligne pheochromocytomen en paragangliomen". Principal investigator: Dr. R.R. de Krijger.

2007 Research Grant from ErasmusMC: "De rol van de SDHB pathway bij het onderscheid tussen benigne en maligne pheochromocytomen en paragangliomen". Principal investigator: Dr. R.R. de Krijger, Erasmus MC, Rotterdam, the Netherlands.

2008 Mechanisms of tachyphylaxis to somatostatin analog treatment. Principal investigator: Dr. L.J. Hofland, Erasmus MC, Rotterdam, the Netherlands.

2009 Polymorphism for the metabolism of serotonin in patients with the carcinoid syndrome (principal investigator).

2009 DutchMEN1 Study Group: database MEN 1 (principal investigator).

2013 Biobank en weefselweekonderzoek van patienten met een neuroendocriene tumor.

2016 OptiNET: Optimization of diagnosis and follow-up of neuroendocrine tumors.

2016 Landelijke von Hippel-Lindau Database

2017 FIBNET: Fibrosis associated with midgut neuroendocrine tumors. Clinical and basic aspects.

2019 ImproveNET: optimizing diagnosis and therapy of neuroendocrine tumors.

2019 The microbiome and NET.

2020 Neuroendocrine Tumor Research Foundation 2020 Accelerator Award Research Grant. Mesenteric fibrosis in small intestinal neuroendocrine tumors: pathogenesis. Together with the group of Prof. M Caplin, Royal Free Hospital, London, UK.

2020 INTENSIVE study IEO 1291 - ClinicalTrials.gov Identifier: NCT04444401. InterNational Registry of SARS-CoV-2 positive neuroendocrine neoplasm patients ((Registro internazionale di pazienti affetti da neoplasia neuroendocrina positivi per SARS-CoV-2) Coordinating center: Istituto Europeo di Oncologia.

2021 KWF 13363 / 2021-Infra: Infrastructure for rare Cancers in the Netherlands: Towards a comprehensive platform for early detection and treatment of rare cancers: FORCE. Project Leader: dr. Annemiek Walenkamp (University Medical Center Groningen / Medical Oncology) Principal Investigator(s): prof. Gerlof Valk (UMC Utrecht / UMC Utrecht Cancer Center) prof.dr. Els Nieveen van Dijkum (Academic Medical Center / Surgery) prof.dr. Morris Swertz (University Medical Center Groningen / Genetics) prof.dr. Ed Schuurung (University Medical Center Groningen / Pathology and Medical Biology) prof.dr. Wouter de Herder (Erasmus University Medical Center Rotterdam / Internal Medicine) dr. Mathilde Jalving (University Medical Center Groningen / Medical Oncology) dr. Heinz-Josef Klumpen (Academic Medical Center / Oncology) dr. Rudolf Fehrmann (University Medical Center Groningen / Medical Oncology)

CLINICAL TRIALS

2003 An open-label, multicenter, phase II study evaluating the safety and efficacy of twice daily dosing of SOM230 in patients with metastatic carcinoid tumors (Study no. CSOM230B2202) (principal investigator).

2005 A multicenter study comparing treatment of patients with neuroendocrine Gastro-Entero-Pancreatic (GEP) tumors with 177Lu-octreotate versus combined 177Lu-octreotate and capecitabine treatment (co-investigator).

2006 A Phase I, multicenter, open-label, randomized study assessing the pharmacokinetics, safety, and tolerability of monthly doses of SOM230 i.m. LAR injection in patients with acromegaly and patients with carcinoid disease. (Study no. SOM230C2110)(principal investigator).

2006 Phase III, randomized, double blind, stratified comparative, placebo controlled, parallel group, multicenter study to assess the effect of deep subcutaneous injections of lanreotide autogel 120 mg administered every 28 days on tumour progression free survival in patients with nonfunctioning entero-pancreatic endocrine tumour (Study protocol 2-55-52030-726) (principal investigator).

2007 - 2018 Studies for obtaining approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) on the use of 177Lu-octreotate as targeted therapy in the

clinical setting. Principal investigators: Prof. Dr. D.J. Kwekkeboom & Prof E.P. Krenning, Erasmus MC, Rotterdam, the Netherlands.

2007 A randomized, double-blind, placebo-controlled, multicenter phase III study in patients with advanced carcinoid tumor receiving Sandostatin LAR(R) and RAD001 10mg/d or Sandostatin LAR(R) and placebo (Study no. CRAD001C2325) (principal investigator).

2009 RAMSETE: A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent Neuro-Endocrine Tumours in Europe (Study no. CRAD001CDE16) (principal investigator).

2009 Endoscopic ultrasound and 11C-5-HTP PET screening for pancreatic neuroendocrine tumors in Multiple Endocrine Neoplasia type 1 and Von Hippel-Lindau disease (principal investigator).

2010 Phase II, open, adaptive, dose escalating, multicentre titration study to assess the efficacy and safety of repeated subcutaneous administration of different doses of BIM 23A760 in patients with carcinoid syndrome (Protocol nr. 8-55-52060-004) - IRB nr. IRBN2009011 HdJ 5. (principal investigator).

2011 RASEEP: A Retrospective Analysis of Safety and Efficacy of Everolimus in GEP-NET patients that showed progression after PRRT trial.

2011 A randomized, open-label phase II multicenter study evaluating the efficacy of oral everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tumors (PNET) - The COOPERATE-2 study. (principal investigator).

2012 A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of GI or lung origin (RADIANT-4). (principal investigator).

2012 A multicenter, two stage, phase II study evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo + BSC in advanced pNET after mTOR failure (Study CBEZ235F2201). (principal investigator).

2013 A Phase 3, Randomized, Placebo-Controlled, Parallel-group, Multi-Center, Double-Blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Refractory to Somatostatin Analog (SSA) Therapy. LX1606-301 (TELESTAR). (principal investigator).

2013 RASEEP-2: A Retrospective Analysis of Safety and Efficacy of PRRT in GEP-NET patients that showed progression after Everolimus or Sunitinib.

2015 Patienten tevredenheidsonderzoek betreffende de thuis injectieservice van somatostatine analoga bij patienten met een neuroendocriene tumor

2015 Efficacy and safety of Somatuline Autogel(R) 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with Somatuline Autogel(R) 120 mg administered every 28 days. NL54223.078.15. (CLARINET FORTE). (principal investigator).

2020 A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET (the NETTER-2 Study; Clinical Trial Protocol CAAA601A22301). EudraCT Number: 2019-001562-15.

2020 A multicenter, open-label post authorization safety study to evaluate the effect of LysaKare(R) infusion on serum potassium levels in GEP-NET patients eligible for Lutathera(R) treatment. (LYSAKARE(R) Clinical Trial Protocol CAAA001A12401). EUDRACT number: 2019-004073-76.

2021 ONCODE - Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors: the PRRT-PARPi study

- Memberships**
- Nederlandse Vereniging voor Endocrinologie (Dutch society for Endocrinology (NVE), the Netherlands).
 - Endocrine Society (USA).
 - European Society of Endocrinology (ESE).
 - ENETS (European Neuroendocrine Tumour Society).
 - Nederlandsche Internisten Vereeniging (Dutch Association of Internal Medicine, NIV).
 - NANETS (North American NeuroEndocrine Tumor Society).

Other Relevant Information

EDITORIAL BOARDS

Editor: Neuroendocrinology: 2004 - 2020.

Editor: Endocrine Related Cancer: 2007 - 2013, Associate Editor: Endocrine Related Cancer: 2013 - present.

Senior Editor: Clinical Endocrinology: 2015 - 2018

Editor: Endocrinology, Diabetes & Metabolism Case Reports: 2013 - present

Deputy Editor ESE Newsletter: 2012 - 2013

Editor ESE Newsletter: 2013 - 2019

. Sectie redacteur Nederlands Tijdschrift voor Geneeskunde: 2018 - present